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ABSTRACT 
 
      Our project was aimed at the development of novel CB1 cannabinoid receptor antagonists that 
may have clinical applications for the treatment of cannabinoid and psychostimulant addiction. 
In this study, we designed, synthesized, and established the CB1 affinity for the 1,5-diaryl-1,2,3-
triazole esters, a series of 4,5-diaryl-1-substituted-1,2,3-triazole analogues and a series of 4,5-
diaryl-2-substituted-1,2,3-triazoles. 
 
     Our research group has been interested in the synthesis of amphibian alkaloids due to their 
interesting biological activities. We have recently developed a general synthetic strategy which 
can rapidly prepare a few amphibian alkaloids simply from the abundant natural product (-)-
cocaine This strategy was first successfully applied to the synthesis of (-)-monomorine. More 
recently, this strategy has also been utilized in the syntheses of both of the enantiomers of cis-
pyrrolidine 225H and (+)-gephyrotoxin 287C. 
 
 
 
 
 
 
Keywords: endocannabinoid system, CB1 receptors, antagonists, drug abuse, binding affinity, 
amphibian alkaloid, formal synthesis, neuronal nicotinic acetylcholine receptor.
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CHAPTER 1 
DESIGN AND SYNTHESIS OF CB1 RECEPTOR LIGANDS 
 
1.1 ABSTRACT 
      This study was aimed at the development of novel CB1 cannabinoid receptor antagonists that 
may have clinical applications for the treatment of cannabinoid and psychostimulant addiction. 
Our original target molecule was carboxamide. The rationale was to incorporate a bioisosteric 
1,2,3-triazole ring into the vicinal diaryl group revealed in the prototypical antagonist/inverse 
agonist SR141716 (Rimonabant)  that was presumed to interact with a unique region in the CB1 
receptors.  
      Based on our preliminary results we identified a novel series of 1,2,3-triazole ester 
derivatives as lead compounds for for biological evaluation.  
      Herein the design rationale, synthesis and CB1 receptor affinity for the 1,5-diaryl-1,2,3-
triazole esters, a series of 4,5-diaryl-1-substituted-1,2,3-triazole analogues and a series of 4,5-
diaryl-2-substituted-1,2,3-triazoles is described. 
 
1.2 INTRODUCTION 
The Endocannabinoid System 
      The endocannabinoid system is a physiological system that is believed to regulate body 
weight, glucose and lipid metabolism, and tobacco dependence. The endocannabinoid system 
consists of three components:  cannabinoid receptors, their endogenous ligands 
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(endocannabinoids), and the enzymes, proteins, and transporters involved in the synthesis and 
degradation of endocannabinoids. 1  
      The research on cannabinoid receptors was stimulated by the identification of the chemical 
structure of Δ 9-tetrahydrocannabinol (1, Δ 9-THC), the major active component of marijuana. 
Although, the central and peripheral actions of marijuana have been studied for over half a 
century and marijuana has been used in medical and recreational applications throughout the 
ages, it has taken many years to understand the action mechanisms.2 The effects of Δ9-THC have 
been assumed to be mediated by the binding of this drug to a certain type of receptors located 
throughout the body, defined as cannabinoid receptors.  
 
Figure 1.1 Δ9-Tetrahydrocannabinol (1, Δ9-THC) 
      Endocannabinoids are endogenous compounds that bind to and functionally activate the same 
receptors Δ9-THC binds to. A tremendous number of studies have contributed to the 
comprehension of the endocannabinoid regulation and function. Unlike many other 
neuromodulators or hormones, endocannabinoids are not synthesized in advance and stored in 
vesicles, they are released “on demand” from their phospholipid precursors in cell membranes.2,3 
To date, five endocannabinoids have been identified. Anandamide (AEA, 2) was the first 
endogenous ligand identified and reported in the early 1990’s. Anandamide together with 2-
arachidonoyl glycerol (2-AG, 3) are the two most studied endocannabinoids.4 
      Anandamide and 2-arachidonoyl glycerol are biosynthesized “on demand” from their 
membrane lipid precursors, N-arachidonoyl-phosphatidylethanolamine (N-ArPE) and sn-1-acyl-
3 
 
2-arachidonoylglycerols (DAGs) respectively.5 Most of the proteins involved in the metabolism 
of Anandamide and 2-arachidonoyl glycerol have been fully characterized, especially the 
enzymes responsible for their biosynthesis and degradation. However, the route for the synthesis 
and inactivation of Virhodamine (4), N-arachidonoyldopanime (NADA, 5), and noladin ether (6) 
still remains unclear. And further efforts are necessary to understand the signaling system of the 
endocannabinoid system. 
 
 
Figure 1.2 Endocannabinoids 
 
Cannabinoid Receptors 
      The identification of the cannabinoid receptors was stimulated by the desire to understand the 
pharmacological and biochemical effects of the psychoactive effects of Δ9-tetrahydrocannabinol 
(Δ9-THC), the major psychoactive component of cannabis. It was believed that the effects of Δ9-
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tetrahydrocannabinol (Δ9-THC) are mediated by occupation of receptors located throughout the 
body. 
      Although the existence of protein receptors for Δ9-tetrahydrocannabinol (Δ9-THC) had been 
indicated for a long time, Allyn Howlett et al., for the first time, provided definitive evidence for 
a cannabinoid receptor. They developed a binding assay established that cannabinoids activated a 
G protein-coupled receptor (GPCR) that inhibited adenylyl cyclase. Their work further showed 
this receptor was present in certain brain regions with a high expression level.4 Furthermore, the 
cannabinoid receptor distribution was successfully mapped with the development of highly 
active cannabinoid receptor agonists.6,7 The existence of cannabinoid receptor was ultimately 
proved by the cloning of a cannabinoid receptor in 1990 by Matsuda et al.8 which was followed 
by the cloning of a second type of cannabinoid receptors three years later in 1993.9 
      Much has been learned about the cannabinoid receptors by determining its localization. The 
localization of cannabinoid receptors was mainly determined using quantitative autoradiography, 
in situ hybridization and immunocytochemsitry.10 The autoradiographic studies performed by 
Herkenham et al. demonstrated significant results about CB1 receptors: a) The CB1 cannabinoid 
receptors are mainly expressed in the central nervous system with high density in the cerebellum, 
hippocampus, and striatum. The CB1 cannabinoid receptors were highly abundant in the brain 
regions that are affected by psychoactive effects of Δ 9-tetrahydrocannabinol (Δ9-THC); b) the 
concentration was low in the brain regions unaffected by tetrahydrocannabinol (Δ9-THC); c) 
CB1 receptors were expressed abundantly on axon terminals. The expression of CB1 receptors 
has also been described with high resolution from immunoctyochemical studies. It was revealed 
that CB1 receptors are expressed at very high levels in a subset of GABAergnic interneurones, 
the cholecystokinin (CCK) containing basket cells and at lower levels on many glutamatergic 
5 
 
terminals throughout the brain. CB1 receptors are largely present on the preterminal axonal 
segment and axons but very little on more proximal axons, dendrites, or the cell body. CB1 
receptors are also found in fat, liver, pancreas, skeletal muscles, and a number of other peripheral 
tissues.11 Conversely, the CB2 cannabinoid receptors are exclusively present in the immune 
system. It has been found in the periphery of the spleen and cells associated with immune system. 
The presence of a third type of cannabinoid receptor has been indicated recently.  
      Cannabinoid receptors (CB1, CB2) belong to the Class A, rhodospin-like family of G 
protein-coupled receptors (GPCRs). The cannabinoid receptors signals primarily through the 
inhibitory G proteins Gi and Go, to a less extend via Gs and Gq/11 with certain agonists. Both the 
CB1 cannabinoid receptor and the CB2 cannabinoid receptors share the similar signaling 
sequence. Upon the binding of cannabinoid ligands on cannabinoid receptors, the cannabinoid 
receptors were stimulated which leads to the activation of adenylyl acyclase, the activation of 
mitogen-activated protein kinases, the inhibition of certain voltage-gated calcium channels and 
the activation of G protein-linked inwardly rectifying potassium channels. The modulation of ion 
channels by CB2 cannabinoid receptors is more variable than that of CB1 cannabinoid receptors. 
CB1 was originally believed to be the “brain type” of receptors because it is among the most 
abundant G protein-coupled receptors in the central nervous system of mammalians. Now it is 
clear that CB1 is predominantly expressed in the central nervous system but also, to a lesser 
extent, in various peripheral organs, while CB2 receptors are mostly expressed in the immune 
system. “The endocannabinoid system appears to be involved in a rising number of pathological 
conditions and hence represents an exciting target for drug discovery.”12 
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CB1 Receptor Ligands 
      The CB1 receptor is pharmacologically activated upon small molecule occupation of the 
binding sites.  Based on structural features, cannabinoid receptor ligands fall into four classes4: 
1. “Classical” Cannabinoids typified by tetrahydrocannabinol (Δ9-THC, 1); 
2. “Non-classical” cannabinoids [ e.g. CP55,940, 7]; 
3. “Aminoalkylindoles” [ e.g. WIN55212-2, 8]; 
4. “Endocannabinoids” [e.g. anandamide, 9]. 
 
 
                     Δ9-THC (1)                                                          CP55,940 (7)                                                              
 
                   WIN55,212-2 ( 8)                                                  Anandamide (9) 
Figure 1.3 Cannabinoid receptor ligands 
 
      These ligands typically exhibit low nanomolar binding affinity for CB1 receptors and 
generally do not exhibit significant differential in binding affinity between the two subtypes of 
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the cannabinoid receptors, CB1 and CB2. Of these ligands, anandamide has been reported to 
exhibit selectivity for CB1 over CB2 with Ki = 61 nM (CB1) and Ki = 1930 nM (CB2). CB1 
receptor agonists inhibit cAMP production through inhibition of adenlyl cyclase, inhibit Ca+2 
influx, activate K+ channels and activate MAP kinase pathways. One of the many indications of 
CB1 receptor agonists is to increase intracellular dopamine levels in brain (striatum) similar to 
cocaine. It is believed that CB1 agonist modulation of dopamine levels in the central nervous 
system is responsible partially for the abuse liability observed for cannabinoid agonists.  
      The CB1 cannabinoid receptor agonists have a great variety of potential pharmacological 
applications including nausea, glaucoma, cancer, stroke, pain, cachexia, and neuronal disorders 
such as multiple sclerosis and Parkinson’s disease.13  
 
 
Figure 1.4 Cannabinoid receptor partial agonists 
 
      Among known cannabinoid receptor agonists there are several compounds exhibiting low 
efficacy agonist profiles in vitro and in vivo. Like the potent cannabinoid receptor ligand CP-
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55,940 (7) and WIN 55212-2 (8), they stimulated [35S]GTPγS binding but were significantly less 
potent and hence they have been designated as partial agonists.14,15 The partial agonists include 
tetrahydrocannabinol (Δ9-THC), BAY59-3704 (10), CB-25 (11) and CB-52  (12). 
 
CB1 Receptor Antagonists 
      The CB1 cannabinoid receptor antagonists bind to CB1 receptors and block the effects of 
CB1 agonists. CB1 antagonists block stimulation of [35S]GTPγS binding and block the inhibition 
of adenlyl cyclase activity. The CB1 cannabinoid antagonists have potential applications in the 
treatment of obesity and nicotine dependence. The CB1 receptor antagonists known so far are 
diarylpyrazoles, or aminoalkylidoles or triazole drivatives.16 
 
 
Firgure 1.5 SR141716A (Rimonabant, 13) 
 
      SR141716A (Rimonabant, 13), the first CB1 receptor antagonist synthesized, was tested in 
humans and then approved as a drug for the treatment of obesity and related comorbidities.  
       Bioisosterism is an important approach frequently used in medicinal chemistry to discover 
new lead compounds based on existing key ligands. It plays a significant role in attenuating 
toxicity, optimizing binding, and altering pharmacokinetics of a lead compound. The three 
dimensional structures of thiazoles, triazoles, and imidazoles and the structure of pyrazole 
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exhibit a high degree of similarity. Consequently, the pyrazole ring in Rimanabant can be 
replaced by such heterocyclic five-membered rings in order to discover bioisosteres, compounds 
that have similar chemical or physical properties and therefore similar biological properties. 
      Based on the structure of Rimonabant, numerous analogues have been synthesized to 
elucidate the structure-activity relationship information and the biological mechanisms. Most of 
those analogues were designed and synthesized based on the 1,5-diarylpyrazole ring as structural 
template, which was believed to be the molecular region binding to CB1 receptors. Various 
structural modifications of the prototype Rimonabant were undertaken and led to new series of 
cannabinoid compounds. Some of those compounds turned out to be CB1 antagonists with good 
potency, CB1/CB2 selectivity, and improved lipophilicity.  
      One of the most important structural modifications was focused on the changes of the C-3 
acyl group. Analogues have been synthesized and evaluated to establish the influence of the 
presence of the carboxamide oxygen from the C-3 position on the binding affinity.17 The 
carboxamide group was replaced by heterocyclic carboxamide bioisosteres, amino alcohols, 
ketones. It was discovered that the potency was diminished relative to Rimonabant when the 
carboxamide oxygen was absent from the pyrazole ring. It was explained by the hypothesis that 
the carboxamide oxygen forms a hydrogen bond with the CB1 receptor binding region. However, 
the functional assay results of those analogues suggested that the carboxamide group contributes 
to the inverse agonist property. Analogues without the carboxamide oxygen were identified as 
neutral antagonists in efficacy evaluations. Moreover, the analogues of Rimonabant consisting of 
long-chain alkyl amide have been synthesized and reported to exhibit good affinity for CB1 
receptors.18 Analogues with alkyl chain longer than six carbons exhibited decreased binding 
10 
 
affinity at CB1 receptors. Branched alkyl amides were generally more potent than the 
corresponding straight alkyl amides same number of carbon atoms.19  
      Based on the experimental and computational studies, the pharmacophoric requirements were 
concluded for the potency of the pyrazole analogues in CB1 binding: a para-substitute phenyl 
ring at the pyrazole C-5 position, a 2,4-dichlorophenyl ring at pyrazole N-1 position, and a 
carboxamide moiety at pyrazole C-3 position.20 
      SAR studies revealed that the C-5 phenyl group was essential for the CB1 binding. 
Substitution at the p-position of the phenyl with a halogen atom or an alkyl chain can effectively 
increase the binding affinity. In a recent study, pentyl chains with a variety of groups attached to 
the terminal carbon were used as the substituents at that position. The resulting analogues 
exhibited excellent binding affinity to CB1 receptors.19    
      Based on Rimonabant as the prototype, ring bioisosterism has been the most widely used 
strategy to design and synthesize cannabinoid antagonists with optimal pharmacological 
properties. The first reported bioisosteric analogues of Rimonabant were 4,5-diarylimidazole-2-
carboxamides synthesized by replacing the pyrazole core with an imidazole ring.21 A series of 
1,2-diarylimidazole-4-carboxamides were also described and structural modifications were 
conducted to established SAR information.22 The biological data clearly demonstrated that for 
both of those two isomeric series of imidazole analogues, the most potent ligands were those 
possessing substitution pattern very similar to that of SR141716A. In addition, most of those 
imidazole analogues showed antagonistic properties in functional assay studies. Some 
compounds displayed affinities for CB1 receptors comparative to that of SR141716A and had 
good oral bioavailability and brain penetration.  
11 
 
 
Figure 1.6 Rimonabant bioisosteric analogues 
 
      The pyrazole core in SR141716A was also replaced by other five-membered bioisosteric 
rings. These included thiazole, oxazole and 1,2,4-triazole derivatives. Those analogues were 
reported to be less potent than the methyl-diarylimidazoles discussed earlier. This difference in 
binding affinity may be attributed to the absence of methyl group which was believed to play a 
very important role in properly orienting the carbonyl group for molecular recognition at the 
CB1 binding pocket. Despite the moderate binding affinity associated with the 1,2,4-triazole 
derivatives, this series provided interesting compounds. The analogue bearing the same 
substituents as SR141716A was found to be an antagonist (14). Another 1,2,4-triazole derivative 
(15) bearing a n-hexyl instead of a carboxamide was reported to be an antagonist both in vitro 
and in vivo. In addition, it was one of the few known CB1 receptor antagonists without inverse 
agonistic properties.23 Tremendous amount of work has also been done researching on the 
structure-activity relationship of the imidazole bioisosteric analogue of SR141716A (16, 17).  
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Figure 1.7 Rimonabant bioisosteric analogues 
 
      In addition to the analogues with five-membered bioisosteric rings, six-membered ring 
replacement of the pyrazole ring in SR141716A has afforded a number of pyridine, pyrimidine 
and pyrazine derivatives. Diarylpyridine analogues with or without the carboxamide group were 
all synthesized and evaluated in binding assay studies. The ether 18, a potent and selective CB1 
agonist, demonstrated that the presence of amide moiety was not necessary for this category of 
compounds. It could be replaced by other functional groups combination with the substituent at 
the pyridine C-5 position, such as the nitrile in 19, to optimize pharmacological profiles.24 The 
introduction of a polar substituent to the pyrazine ring provided analogues 20 that were less 
lipophilic and more bioavailable. Compound with phenyl group 21 as the central ring still 
exhibited good binding to CB1 receptor. It indicated that the presence of a heterocycle is not 
strictly required for a CB1 antagonist.25 
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Figure 1.8 Six-membered bioisosteric analogues of Rimonabant 
 
Drug Abuse 
      Behavioral pharmacologists are particularly interested in the roles of CB1 receptors because 
of their selective presence in the central nervous system and their association with brain-reward 
circuitry.14 The mesocorticolimbic dopamine system has been implicated in mediating the effects 
of several drugs. The mesocorticolimbic dopamine system is believed to be the primary region of 
the brain mediating the effects of several drugs and is closely associated with brain-reward 
circuitry mechanisms. The mesocorticolimbic dopamine system includes neurons in the ventral 
tegmental areaand corresponding projections into the forebrain regions.15 Even though CB1 
receptors do not reside on the mesencephalic dopaminergic neurons, they are located in these 
regions.2 CB1 receptor agonists elevate dopamine levels, while CB1 receptor antagonists or 
14 
 
inverse agonists can attenuate the dopamine level elevations associated with drug abuse and 
diminish the stimulation of dopaminergic activity in the reward circuitry of the brain and 
attenuate the effects of drug abuse. Therefore, the development of CB1 antagonists as potential 
therapeutic agents for drug abuse is straightforward. While the CB1 antagonist  Rimonabant did 
not show to have an effect on cocaine and amphetamine self-administration, it has been reported 
to reduce rat cocaine-primed and cue-induced reinstatement studies with CB1 antagonist CB1 
antagonists have been shown to block the effects of Δ9-THC and appear to be devoid of abuse 
liability.16  
 
1.3 RESULTS AND DISCUSSION 
      The program, illustrated in Scheme 1.1, includes chemical synthesis, in vitro biological 
evaluation, and in vivo biological evaluation. Phase 1 of the study will consist of rational drug 
design and synthesis. Novel analogues will be designed based upon lead structures identified in 
our preliminary studies and supported by computational studies. In phase 2, compounds will be 
evaluated in vitro studies to identify structural requirements for high affinity binding. The 
binding affinity results will be used to advance compounds to in vitro efficacy studies as well as 
provide feedback information for the optimization of compound structures to identify more 
potent ligands. Phase 3 of the study will consist of in vitro characterization of compound efficacy 
and identify CB1 antagonists, agonists, or inverse agonists. Because of their different action 
mechanisms and potential therapeutic values, inverse agonists and partial agonists will be 
directed to another program. Compounds that elicit neutral antagonist efficacy will be advanced 
to the blood-brain barrier permeability evaluations. Compounds that exhibit good blood-brain 
barrier permeability will be advanced to in vivo evaluation of antagonist efficacy. 
15 
 
 
 
Scheme 1.9 Flowscheme of CB1 receptor rug discovery program 
       Compounds with poor blood-brain permeability will be re-evaluated in the rational drug 
design process to improve their physical properties to improve permeability. Finally, phase 5 will 
establish in vivo antagonist activity for compounds that have met the goals of in vitro efficacy 
and blood brain permeability. Those compounds that exhibit good in vivo antagonist efficacy 
will be submitted to the National Institute of Drug Abuse and serve as a lead compounds in 
future studies aimed at developing them further as drug abuse medications. The various phases 
of the program all go simultaneously with each phase contributing to the refinement of the ligand 
structure. 
16 
 
 
Figure 1.9 Initial target  
 
      In reviewing the literature about CB1 receptor antagonists, we noticed that the 1,2,3-triazole 
analogues were absent from the pool of SR141716A bioisosteric analogues. Our initial design of 
the target compound was based upon prototypical structure of SR141617A and its related 
compounds discussed in the literature. The design rationale was to incorporate the 1,2,3-triazole 
ring with the vicinal diaryl system. This led to the compound 22. This design was supported by 
preliminary computational study. As illustrated in Figure 1.10, for the AM1 geometry optimized 
structures, a 1,2,3-triazole ring in 2 could replace the pyrazole ring and provide good overlap 
with SR141716A in the diaryl groups which was believed to be the molecular region binding to 
CB1 receptors. It was not clear at that time how the juxtaposition of the alignment of the 
carboxamide moieties of 22 relative to SR141716A would affect molecular recognition at CB1 
receptors. Molecular modeling studies reported for analogues of SR141716A had suggested that 
increased steric bulk at C4 could be tolerated. This suggested that the carboxamide at C4 of 22 
may not have detrimental effect on CB1 binding. Furthermore important to the target selection 
was that computational logP (clogP) values for the 1,2,3-triazole derivatives typically exhibited a 
trend of improved lipophilicity over corresponding pyrazole or 1,2,4-triazole isomers of similar 
substitution and functionality. Although the ClogP values may vary from actual logP values, this 
17 
 
trend of decreased lipophilicity was encouraging for us to move forward. Based on this analysis, 
we identified the 1,5-diaryl-1,2,3-triazole as our initial target for synthesis. 
 
Figure 1.10 Preliminary computational study 
 
      To synthesize the target molecule, the key was to construct the 1,2,3-triazole ring with the 
right regiochemistry. One of the most attractive strategy was the 1,2,3-triazole ring system was 
to exploit the 1,3-dipolar cycloaddition reaction of an azide and a terminal alkyne (Scheme 
1.2).26, 27 When Cu(I) salt was used as catalyst for this reaction, the product was 1,4-
disubstituted-1,2,3-triazole. However the reaction of magnesium actylide and terminal alkyne 
give the 1,5-disubstituted-1,2,3-triazole exclusively. This strategy would allow rapid 
regioselective ring construction of the target molecules and provide suitable intermediates for 
parallel synthesis of potential analogues.  
18 
 
 
 
Scheme 1.2 The strategy to synthesize 1,2,3-triazoles  
 
       As one the building blocks for the cycloaddition reaction, 2,4-dichloropheynlazide 24 was 
required to be synthesized. Unlike the preparation of alkyl azides, there are only few effective 
methods available for the synthesis of aryl azides. Aryl azides were generally synthesized by 
diazotization of aryl amine followed by the treatment of sodium azide. An alternative method 
developed recently was to treat the corresponding amines with triflyl azide.28 As illustrated in 
Scheme 1.3, this reaction worked well on 4-chloroaniline to provide 4-chlorophenyl azide 23 in 
a 82% yield. It did not furnish useful quantities of the 2,4-dichlorophenyl azide. Moreover, triflyl 
azide was not commercially available nor could it be stored for a long time. It needed to be 
freshly prepared every time to synthesize phenyl azide. Fortunately, the Ullmann-type of 
conversion iodobenzene catalyzed by CuI with trans-1,2-di(aminomethyl)-cyclohexane as ligand 
worked efficiently on both 4-chloroiodobenzene and 2,4-dichloroiodobenzend.30 4-Chlorophenyl 
azide was prepared in a 89% yield and 2,4-dichloropheny benzene in a 54% yield from 2,4-
dichloroiodobenzene. All the reagents required for the synthesis of azide in this reaction were 
commercially available and the reaction could be conducted in a gram-scale. 
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Scheme 1.3 Synthesis of azide 
Reagents and conditions: a) H2O/CH2Cl2, 0 º Cb) TfN3, aq. CuSO4, Et3N, CH2Cl2/MeOH, rt, 2 h; 
c) TfN3, aq. CuSO4,  Et3N, CH2Cl2/MeOH, rt, 2 h; d) NaN3, Sodium ascorbate, CuI (10% mol), 
Ligand (15 mol%), DMSO/H2O, 50 ºC, 1 h; e) NaN3, Sodium ascorbate, CuI (10% mol), Ligand 
(15 mol%), DMSO/H2O, 100 ºC, 2 h 
 
      Since the mono-chlorophenyl azide 23 was more readily available by the synthesis, it was 
employed as the model to explore the potential of the cycloaddition approach and to examine the 
reaction conditions. Additionally, the resulting analogues with monochloro-substituted phenyl at 
N-1 position could be evaluated for CB1 binding and provide SAR information about 
substitution at this position. The proposed mechanism of the cycloaddition reaction was 
illustrated in Scheme 1.4.27 The reaction started with the nucleophilic attack of the acetylide on 
the terminal nitrogen of the azide to form a linear intermediate which spontaneously closed to 
give the 4-metallotriazole 25 which leads to 1,5-disubstituted-1,2,3-triazole 26 when treated with 
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an electrophile. In the excess of azide, the intermediate 4-metallotriazole 25 reacts with the 
second azide and gives the side product 27. 
 
Scheme 1.4 Proposed mechanisms of 1,2,3-triazole formation 
 
      To monitor the process of the one-pot three-step reaction and to optimize the yield for this 
reaction, the cycloaddition adduct was first directly treated with aqueous NH4Cl solution. The 
evaluation of the resultant 4-unsubstitute analogues would provide important SAR information 
about the effects of substitution at this position on the binding of 1,2,3-triazoles to CB1 receptors. 
The best yield (85%) was obtained when freshly made azide in THF was added to the acetylide 
and was heated for 2 hours at 50 ⁰C with a small amount of acetylene remaining unreacted. 
Excessive azide or extended reaction time led to decreased yield due to the addition of a second 
molecule of azide to the 4-magnesio-1,2,3-triazole. To synthesize the target carboxamide 
analogue 22, the carboxylic acid 31 was proposed as an intermediate from which the 
carboxamide could be synthesized through a straightforward amidation. When the cycloaddtion 
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intermediate 28 was treated with CO2, only the hydrolyzed product 4-unsubstituted-1,2,3-triazole 
29 was obtained because of the moisture introduced by CO2 stream. As an alternative synthetic 
route, methyl ester 30 was synthesized and concomitant hydrolysis gave the carboxylic acid 31 
in a good yield. The methyl ester 30 was prepared by capturing the 4-magnesio-1,2,3-triazole 
with methyl chloroformate.  
 
 
Scheme 1.5 Synthesis of target compound 
Reagents and conditions: a) 1. EtMgCl, THF, rt, 1 h; 2. 23 or 24, THF, 50 oC, 2 h; b) 1 N NH4Cl; 
c) CO2, 0 oC; d) ClCOOMe, THF, 0 oC; e) KOH, MeOH, reflux; f) DIPEA, HBTU, CH3CN, 1-
aminopiperidine. 
 
 
 
22 
 
Cmpda Code                           ClogPb Ki (nM)c 
 
22a 
      
      HS69 
                              
                              5.33 
  
590 ± 170 
22b 
29b 
     HS60 
      HS53-2 
                              4.69                  
                             4.46 
54%d    
6,900 ± 1,300 
29a      HS57-2                               5.11 1,420 ± 266 
30b      HS53-1                               4.68 4,400 ± 760 
30a      HS57-1                               5.32 66 ± 7.0 
    
aAll compounds were tested as the freebase. 
b See Ref. 30. 
cAll values are the mean ± SEM of three experiments performed in triplicate. 
dPercent inhibition at 100µM. 
 
Table 1.1 Inhibition of [3H]SR141716A at CB1 Receptors 
 
      As illustrated in Table 1.1, the binding affinities for CB1 receptors of the three 1,5-diaryl-
1,2,3-triazoles were determined in vitro by displacement of [3H]SR141716A for CB1 receptors 
in rat brain. The Ki values summarized in Table 1.1 indicate that the initial SR141716A analogue 
carboxamide 22a exhibited only modest binding for CB1 receptors (Ki =590 nM). The C4-
unsubstituted analogue exhibited only micromolar affinity for CB1 receptors. It was even less 
potent than the bulky carboxamide. It suggested that substitution at this position of the 1,2,3-
triazole ring is favorable for CB1 receptor binding and structural modification at this position 
may lead to compounds with optimal pharmacological profiles. The N-1 monochloro phenyl 
analogues 29b, 30b, and 22b were less potent than the corresponding N-1 dichloro phenyl 
analogues 29a, 30a, and 22a. However, it was serendipitous to find that the simple ester 
analogue 30a exhibited potent affinity for CB1 receptors. This result validated the previous 
hypothesis that 1,2,3-triazole ring was suitable replacement for pyrazole ring in SR141716A. It 
also indicated that an amide moiety at C4-position was not essential for high binding at CB1 
receptors, which updated the SAR information based on previous studies on other bioisosteric 
SR141716A analogues. More important for the future studies, it provided a very promising 
compound as a new lead compound.                                                                                                 
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      Compared with the target analogue and even SR141716A (Table 1.2), methyl ester 30a had a 
few desirable pharmacological features. First of all, it is near one order of magnitude more potent 
than the target compound and its Ki value was already in the same range with that of SR141716A. 
It also has a significantly smaller molecular weight than those of 30a and SR141716A. It has a 
much lower ClogP value than that of SR141716A.  
 
 
 
 
Cmpd      Ki (CB1) nM      ClogP MW 
 
30a 
 
22a 
 
SR141617A 
      
66  
 
590 
 
11.5a  
                              
   5.32   
 
   5.33  
 
    6.26                         
  
383 
 
451 
 
464 
aTaken form reference 31. 
Table 1.2 The properties of lead compound 
      More importantly, the ester moiety may lead to a significant increase in compound 
metabolism since esters are typically more readily hydrolyzed than amides in vivo. This is 
extremely important in lieu of the long half-lives typically observed for cannabinoids. Ester 
derivatives will undoubtedly be more susceptible to metabolism and have shorter duration of 
action than amide or hydrazide analogues. Although the measurement of ligand half-lives is not 
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part of this study, the development of an ester-based ligand would be an important step toward 
the development of shorter acting cannabinoids with better safety profiles. Therefore, methyl 
ester was identified as a new lead compound for further studies in the development of 1,2,3-
triazoles as CB1 antagonists. 
       
 
Scheme 1.6 Synthesis of esters 
Reagents and conditions: a) 1. EtMgCl (2 N in THF), THF, rt, 1 h; 2. 2,4-dichlorophenyl azide, 
50 ºC, 2 h; b) ClCOOR, THF, 0 ºC; c) cyclohexanol, n-BuLi, THF, 0 ºC, 2 h. 
 
      As illustrated in Scheme 1.6, a series of 1,2,3-triazole analogues with varying ester groups 
were prepared to investigate how lipophilicity and steric effects affect the binding of the ester to 
CB1 receptors. They were synthesized using the procedures described earlier for the methyl 
esters. The 4-magnesio-1,2,3-triazole intermediate was captured with a number of alkyl 
chloroformates. Each of the analogues could be synthesized in gram-scale. But since only a small 
quantity of product was required for the binding assay studies, only the cycloaddition reaction 
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was conducted in a gram-scale. Then the solution of cycloaddition adduct in THF was separated 
into a number of portions and each portion was treated with a different commercially available 
chloroformate to provide the corresponding 4-alkoxycarbonyl-1,5-diaryl-1,2,3-triazole. The 
cyclohexyl ester derivative 38 was prepared by a simple transesterification from the methyl ester 
30a.  
      As shown in Figure 1.11, the X-ray crystallographic analysis of 4-methoxycarbonyl-1,5-
diaryl-1,2,3-triazole served to confirm the regioselectivity of the cycloaddition reaction and 
unequivocally established the regiochemistry of the 1,2,3-triazole ring system.  
 
Figure 1.11 ORTEP Drawing of 4-methoxycarbonyl-1-(4-chlorophenyl)-5-(2,4-dichlorphenyl)-
1,2,3triazole 30a.32 
 
 
      The esters were evaluated in vitro for binding affinity at CB1 receptors (Table 1.3). The n-
propyl ester 33, with a Ki value slightly higher than SR141716A, was the most potent derivative 
of the series. We noticed that it exhibited similar lipophilicity to that of SR141716A. The phenyl 
ester 36 also exhibited high affinity for CB1 receptors, but the affinity of the benzyl ester 37 was 
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somehow diminished, even though they share very similar lipophilicity. The larger alkyl esters 
exhibited high lipophilicity and were difficult to handle in the binding assay. Preliminary binding 
studies indicated diminished binding affinity relative to propyl ester. In general, analogues with 
either decreased or increased lipophilicity relative to SR141716A exhibited diminished affinity. 
It seems to suggest that a narrow window of lipophilic character may exist for binding of these 
triazoles at CB1 receptors. 
 
Cmpda                   Code                     R                                         ClogPb                         Ki (nM)      
SR141716A                                                                                    6.26                               11.5c 
30a                        HS57-1                Methyl                                  5.32                               66           
32                          HS57-3                Ethyl                                     5.68                              180 
33                          HS57-4                n-Propyl                                6.21                              4.6 
34                          HS57-5                n-Butyl                                  6.70                              I.R.d               
35                          HS57-6                n-Hexyl                                 7.62                              I. R. 
36                          HS57-8                Phenyl                                   6.83                              11 
37                          HS57-9                Benzyl                                   6.85                              97 
38                          HS57-7                c-Hexyl                                 7.23                              240 
______________________________________________________________________________                                                                                                                                                           
aAll compounds were tested as the freebase. 
b See Ref. 30. 
cAll values are the mean ± SEM of three experiments performed in triplicate. 
d Inconsistent results. 
 
Table 1.3 Inhibition of [3H]SR141716A at CB1 Receptors 
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Figure 1.12 
 
      The second class of compounds prepared were based on the 4,5-diaryltriazole ring system. 
They were prepared to investigate the effects of the orientation of triazole system on CB1 
receptor affinity. Preliminary computational study confirmed that 4,5-diaryltriazole could also 
provide good overlap with SR141716A. In this vein, the 4,5-diarytriazoles would be expected to 
be equipotent to 1,5-diaryltriazoles. In addition, the 4,5-diaryltriazoles typically offer the 
advantage of lower lipophilicity over the corresponding 1,5-diarytriazoles. A series of 4,5-
diaryltriazole derivatives were designed and synthesized  with three very interesting compounds 
as structure stereotype: our lead compound 30a, triazole 39 has been the only reported neutral 
antagonists. 40 exhibited a nanomolar binding potency.  
       In the synthesis of 4,5-diphenyl-1,2,3-triazoles (Scheme 1.7), the acetal azide was selected 
to be the reaction partner of the 1,3-dipolar cylcoaddition reaction for the consideration of further 
functionalization at a later stage. The acetal group was stable in the early stage reactions, but 
when transformed to the aldehyde, it can react with a number of reagents to prepare a variety of 
analogues.   
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      The 1,3-dipolar cycloadditon reaction of azide 41 and the alkyne gave a 4-magnesio-1,2,3-
triazole intermediate which was treated with elemental iodine giving 42. The heterocyclic 
aromatic iodide 42 was converted into the 4,5-diphenyl-1,2,3-triazole through Suzuki cross 
coupling reaction with 2,4-dichlorophenylboronic acid.    
 
 
Scheme 1.7 
 
Reagents and conditions: a) NaN3, DMSO/H2O, 100 ºC, 2 h; b)  1. EtMgCl (2 M in THF), THF, 
rt, 1 h; 2. 2,4-dichlorophenyl azide, 50 ºC, 2 h; 3. I2, THF, 10 min; c) 2,4-Dichlorophenylboronic 
acid, Pd2(dba)3 (5%mol), PCy3 (12%mol), K3PO4 (1.7 equiv), THF/H2O, 110 ºC, 16 h; d) Me3SiI, 
CHCl3, rt, 1 h. 
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Table 1.4 Suzuki Cross Coupling 
 
       As demonstrated in Table 1.4, we focused on the protocols that have been reported to 
successfully work on heterocyclic substrates especially the nitrogen containing heterocycles. 
Although essentially no desired product was determined from the first two reaction we ran 
(Entry 1, Entry 2), the methodology developed by Fu and coworkers gave the product in a 62% 
for the first run. With a simple screening of the reaction conditions, the desired product was 
obtained in an excellent yield (98%). 
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Scheme 1.8 
Reagents and conditions: a) Ph3P(Br)(CH2)3CH3, t-BuOK, THF, 0 ºC, 1.5 h; b) H2, 10% Pd/C, 
MeOH, rt, overnight; c)  Ph3P(Br)CH2CH3, t-BuOK, THF, 0 ºC, 1.5 h; d) H2, 10% Pd/C, MeOH, 
rt; e) NaClO2, NaH2PO4, 2-Methyl-2-butene, Acetone/H2O, rt, 2 h, overnight; f) TMSCHN2, 
toluene/MeOH, rt, 10 min. 
 
 
      With aldehyde 44 at hand, a number of analogues with different groups at N-1 position were 
synthesized. Wittig olefination reaction of 44 with Ph3P(Br)(CH2)3CH3 or Ph3P(Br)CH2CH3 gave 
45 and 47 respectively which were reduced to 46 and 48 by a simple hydrogenation. Aldehyde 
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44 was efficiently oxidized to carboxylic acid 49 using sodium chlorite as oxidizing agent. 
Carboxylic 50 was then methylated giving ester 50.  
 
 
Scheme 1.9 
Reagents and conditions: a) NaBH4, MeOH, 0 ºC; b) DAST, CH2Cl2,  -78 ºC to rt; c) TsCl, 
Pyridine, rt, 15 min; d) LiCl, Ethanol, reflux, 12 h; e) LiBr, Acetone, reflux, 16 h. 
 
      Aldehyde 44 was reduced to alcohol 51 which was also converted into fluoride 53. When the 
hydroxyl group in 51 was transformed to tosylate, a better leaving group, chloride 54 and 
bromide 56 were prepared from tosylate 53.   
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Scheme 1.10 
Reagents and conditions: a) 1. EtMgCl (2 M in THF), THF, rt, 1 h; 2. Benzyl azide, 50 ºC, 2 h; 3. 
I2, THF, 10 min; b) 2,4-Dichlorophenylboronic acid, Pd2(dba)3 (5%mol), PCy3 (12%mol), K3PO4 
(1.7 equiv), THF/H2O, 110 ºC, 16 h; c) t-BuOK (1 M in THF), O2, DMSO, rt, 2 h; d) NaH, DMF, 
Benzyl bromide. 
 
      The N2-substituted-4,5-diphenyl-1,2,3-triazole analogues were synthesized from the 
intermediate N1-H-4,5-diphenyl-1,2-3-triazole 58. No methodology available to prepare 58 
directly and it had to obtained from the deprotection of a N1-substituted-4,5-diphenyl-1,2,3-
triazole. Therefore, the selection of the azide for the 1,3-dipolar reaction was important. The 
azide functional groups associated with the azide had to be stable enough through the Grignard 
ring closure reaction and the following Suzuki cross coupling. At a later stage, the functional 
group should be removed readily to release an active hydrogen. Commercially available benzyl 
azide was a great candidate for our synthesis.  
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      The 4-magnesio-1,2,3-triazole intermediate was trapped with elemental iodine giving 56 
which served as the coupling partner for the following Suzuki reaction under the reaction 
conditions described previously. Although the most employed hydrogenation could not remove 
the benzyl group from triazole 57, a novel methodology reported by Aubrey A. Haddach et. al. 
successfully worked on our substrate and gave 58  in a high yield.35 
 
 
Figure 1.13 
      With the active hydrogen, 58 was treated with sodium hydride and reacted straightforwardly 
with a variety of electronphilic groups giving nine N2-substituted-4,5-diphenyl-1,2,3-triazole 
analogues. They are 59, butyl ester 60, methyl ester 61, hexyl analogue 62, propyl analogue 63, 
alcohol 64, fluoride 65, chloride 66, and bromide 67.  
      The binding affinity results of N1-substituted-4,5-diphenyl-1,2,3-triazoles and N2-
substituted-4,5-diphenyl-1,2,3-triazoles were summarized in Table 1.5. Although most of the 
analogues only exhibited modest potency, the fluoride 65 (Ki = 72 nM) and the chloride 66 (Ki = 
80 nM) were potent enough to be advanced into further biological evaluations 
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Cmpda                   Code                  R or R’                                ClogPb                         Ki (nM)      
SR141716A                                                                                    6.26                               11.5c 
45                          HS179                R = C6H11                              6.66                               I.R.d          
48                          HS192                R = C3H7                               5.58                               152 
50                          HS183                R = CH2COOMe                   4.34                               247 
51                          HS184                R = CH2CH2OH                    4.03                               163 
52                          HS193                R = CH2CH2F                        4.93                               420 
57                          HS142                R = CH2C6H5                         6.55                               187         
59                          HS216                R’ = CH2C6H5                             7.44                               230 
60                          HS147                R’ = COOBu                         5.55                  30% inhibitione 
61                          HS226                R’ = CH2COOMe                  5.23                               855 
64                          HS 230               R’ = CH2CH2OH                   4.92                               660 
65                          HS232                R’ = CH2CH2F                       5.82                              72 
66                          HS251                R’ = CH2CH2Cl                      6.37                              80 
67                          HS265                R’ = CH2CH2Br                      6.43                              I.R.d 
______________________________________________________________________________                                                                                                                                                           
aAll compounds were tested as the freebase. 
b See Ref. 30. 
cAll values are the mean ± SEM of three experiments performed in triplicate. 
d Inconsistent results. 
ePercent inhibition at 100 µM 
 
Table 1.5 Inhibition of [3H]SR141716A at CB1 Receptors 
 
1.4 CONLUSIONS 
      We started with designing the SR141716A derivative 22a as our target molecule and 
developed chemical synthesis to prepare this compound. Our preliminary binding assay results 
revealed the ester 30a was 10-fold more potent than 22a. Better potency, together with other 
more optimal drug-like properties, ester 30a was chosen to be our lead compound. With this lead 
compound, a series of esters (32-38), N1-substituted-4,5-diphenyl-1,2,3-triazoles (45-55), and 
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N2-substituted-4,5-diphenyl-1,2-3-triazoles (59-67) were synthesized. Six compounds (30a, 33, 
36, 37, 65, 66) exhibited good potency binding to CB1 receptors (Ki <100 nM) and they are 
currently being evaluated to determine efficacy. Based on these results, an extensive study is 
undergoing in our research laboratory searching for novel selective CB1 receptor antagonists.   
 
1.5 EXPERIMENTAL SECTION 
General Experimental Methods 
      All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous dichloromethane was purchased from Mallinckrodt Baker, Inc. 
Research Technology Branch, National Institute on Drug Abuse. Proton and carbon NMR were 
recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer at ambient temperature 
in deuterated chloroform (CDCl3) from Cambridge Isotope Laboratories, Inc. 1H NMR chemical 
shifts are reported as δ values (ppm) relative to tetramethylsilane. 13C NMR chemical shifts are 
reported as δ  values (ppm) relative to chloroform-d (77.0 ppm). Melting points (mp) were 
measured with an Electrothermal R Mel-Temp apparatus and are uncorrected. 
 
 
      Triflyl azide Sodium azide (1.17 g, 18 mmol) was dissolved in a mixture of 4 mL water and 
1.5 mL CH2Cl2 in a 20 mL glass vial. The mixture was cooled to 0 ⁰C in an ice-water cold bath 
and trifluorosulfanic anhydride (0.85 g, 0.51 mL, 3 mmol) was added dropwise. Upon the 
completion of addition, the vial was sealed by a screw cap. The reaction was stirred at 0 ⁰C for 
2.5 hours. The mixture was poured into 10 mL of ice water and extracted with CH2Cl2. 
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Combined organic portions were washed by sat. NaHCO3 aqueous solution. This triflyl azide 
solution was directly introduced to the following step.  
 
 
4-Chlorophenyl azide (23) Aniline (130 mg, 1.02 mmol) was dissolved in 1 mL of CH2Cl2 in a 
20-mL glass vial. Triethylamine (0.42 mL) was added by one portion, followed by the addition 
of a solution of CuSO4.5H2O (13 mg in 0.25 mL H2O). To this solution was added the freshly 
made triflyl azide described above. MeOH was added dropwise until the solution was made 
homogeneous and the color of the reaction changed from light blue to dark. The reaction vial 
was sealed by a screw cap. The stirring continued for 2.5 hours until the process of reaction 
stopped indicated by TLC. The mixture was partitioned between 10 mL sat. NaHCO3 and 10 mL 
CH2Cl2. The organic layer was separated. The aqueous layer was extracted with CH2Cl2 (2 x 10 
mL). Combined organic fractions were washed by sat. NaCl, dried on anhydrous MgSO4, filtered, 
and concentrated in vacuo. The dark brown oily residue was purified by a silica gel column 
eluting with hexanes affording 4-chlorophenyl azide 23 (125 mg, 82%) as a slightly yellowish oil. 
Rf = 0.58 (CH2Cl2/hexanes = 1:9).  
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      2,4-dichlorophenyl azide (24) 2,4-Dichloroaniline (172 mg, 1 mmol) was dissolved in 1 mL 
of CH2Cl2 in a 20-mL glass vial. Triethylamine (0.42 mL) was added by one portion, followed 
by the addition of a solution of CuSO4.5H2O (13 mg in 0.25 mL H2O). To this solution was 
added the freshly made triflyl azide from trifluorosulfanic anhydride (0.85 g, 0.51 mL, 3 mmol) 
by the procedure described above. MeOH was added dropwise until the solution was made 
homogeneous and the color of the reaction changed from light blue to dark. The reaction vial 
was sealed by a screw cap. The stirring continued at room and reaction process was monitored 
by TLC. After 2 hours, only a small amount of product was observed and longer reaction time up 
to 24 hours did not seem to drive the reaction. The mixture was partitioned between 10 mL sat. 
NaHCO3 and 10 mL CH2Cl2. The organic layer was separated. The aqueous layer was extracted 
with CH2Cl2 (2 x 10 mL). Combined organic fractions were washed by sat. NaCl, dried on 
anhydrous MgSO4, filtered, and concentrated in vacuo. The dark brown oily residue was purified 
by a silica gel column eluting with hexanes affording 2,4-dichlorophenyl azide 24 (15 mg, 8%) 
as a slightly yellowish oil. Rf = 0.2 (CH2Cl2/hexanes = 1:9).  
 
 
      4-Chlorophenyl azide (23)  NaN3 (3.25g, 50 mmol) was suspended in the mixture of DMSO 
(25 mL) and H2O (5 mL). The reaction apparatus was degassed and then filled with N2. Sodium 
ascorbate (99.0 mg, 0.5 mmol) and CuI (190 mg, 1 mmol), the ligand (S, S)-(+)-N,N’-Dimethyl-
1,2-cyclohexanediamine (213 mg, 1.5 mmol), and 4-chloro-iodobenzene (2.38 g, 10 mmol) were 
added to the flask consecutively. The mixture was heated at 100 ⁰C. When the progress of the 
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reaction was stopped, it was worked up by a mixture of brine (50 mL) and CH2Cl2 (50 mL). The 
aqueous phase was extracted with CH2Cl2 (50 mL ×  2). The combined organic phases were 
washed with brine (30 mL ×  3), dried over anhydrous MgSO4, and concentrated in vacuo. The 
residue was purified by a short flash chromatography (SiO2, Hexanes) affording 4-chlorophenyl 
azide 23 (1.41g, 9.2 mmol). Rf = 0.5 (Hexanes).  
 
 
      2,4-Dichlorophenyl azide (24)  NaN3 (3.25g, 50 mmol) was suspended in the mixture of 
DMSO (25 mL) and H2O (5 mL). The reaction apparatus was degassed and then filled with 
Argon. Sodium ascorbate (99.0 mg, 0.5 mmol) and CuI (190 mg, 1 mmol), the ligand (S, S)-(+)-
N,N’-Dimethyl-1,2-cyclohexanediamine (213 mg, 1.5 mmol), and 2,4-dichloro-iodobenzene 
(2.73 g, 10 mmol)were added to the flask consecutively. The mixture was heated at 100 ⁰C. 
When the progress of the reaction was stopped, it was worked up by a mixture of brine (50 mL) 
and CH2Cl2 (50 mL). The aqueous phase was extracted with CH2Cl2 (50 mL × 2). The combined 
organic phases were washed with brine (30 mL ×  3), dried over anhydrous MgSO4, and 
concentrated in vacuo. The residue was purified by a short flash chromatography (SiO2, Hexanes) 
affording 2,4-dichlorophenyl azide (24) (0.846 g, 4.5 mmol). Rf = 0.2 (Hexanes). 1H NMR (400 
MHz, CDCl3) δ  7.40 (s, 1H), 7.27 (dd, J = 22, JJ = 6), 7.105 (d, J = 22). 13C NMR (CDCl3) δ 
136.2, 130.8, 130.6, 128.3, 120.6, 102.6. 
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      1,5-bis(4-Chlorophenyl)-1H-1,2,3-triazole Under N2, a solution of 4-chlorophenyl azide 23 
(69 mg, 0.50 mmol) in 2 mL was added dropwise to ethyl magnesium chloride (0.25 mL, 2 M in 
THF). Stirring was continued at 50 ⁰C for 1 hr. Then a solution of freshly made chlorophenyl 
azide (76 mg, 0.50 mmol) in 1 mL of  THF was added dropwise. The mixture was stirred at room 
temperature for 2 hr. and then heated to 50 ⁰C for 1 hr. The reaction was cooled down to 0 ⁰C 
quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). The organic fraction was 
separated. The aqueous fraction was extracted with EtOAc (30 mL ×  2). Combined organic 
fractions were washed with brine (30 mL), dried on anhydrous MgSO4, filtered, and concentrated 
in vacuo. The residue was purified by a flash chromatography (SiO2, EtOAc/Hexanes = 1/5) 
affording 29b (126 mg, 87%) as a yellowish oil. 1H NMR (400 MHz, CDCl3) δ 8.18 (s, 1H), 
7.64-7.30 (m, 8H). 13C NMR (CDCl3) δ 136.8, 135.8, 135.5, 134.9, 133.7, 130.0, 129.8, 129.5, 
126.4, 125.0. Anal. Calcd for C14H9Cl2N3 : C, 57.95; H, 3.13; N, 14.48. Found: C, 58.08; H, 3.14; 
N, 14.35. 
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      Methyl 1,5-bis(4-chlorophenyl)-1H-1,2,3-triazole-4-carboxylate (30b) Under N2, a 
solution of 4-chlorophenyl azide 23 (205 mg, 1.50 mmol) in 2 mL was added dropwise to ethyl 
magnesium chloride (0.75 mL, 2 M in THF). Stirring was continued at 50 ⁰C for 1 hr. Then a 
solution of freshly made chlorophenyl azide (230 mg, 1.50 mmol) in 2 mL of  THF was added 
dropwise. The mixture was stirred at room temperature for 2 hr. and then heated to 50 ⁰C for 1 hr. 
The solution was cooled down to room temperature and added dropwise to the solution of methyl 
Chloroformate (184 mg,1.95 mmol) in 5 mL THF at -20 ⁰C. After stirring for 10 minutes, the 
reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). The organic 
fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). Combined 
organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
EtOAc/Hexanes = 1/5) affording 30b (350 mg, 67%) as a white solid. Mp: 172-173 ⁰C. 1H NMR 
(400 MHz, CDCl3) δ 7.60-7.40 (m, 8H), 3.77 (s, 3H). 13C NMR (CDCl3) δ 140.0, 137.0, 136.8, 
136.0, 135.4, 134.1, 131.7, 139.9, 139.2, 126.5, 123.8, 52.4. Anal. Calcd for C16H11Cl2N3O2 : C, 
55.19; H, 3.18; N, 12.07. Found: C, 55.43; H, 3.21; N, 12.07. 
 
 
      1,5-bis(4-Chlorophenyl)-N-(piperidin-1-yl)-1H-1,2,3-triazole-4-carboxamide (22b) 
Methyl ester 30b (306 mg, 0.88 mmol) was taken up in KOH (45 wt% in water, 2 mL) + 20 mL 
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MeOH and heated to reflux for 2 hours. The reaction was cooled to room temperature and 
concentrated in vacuo. The residue was dissolved in 3 mL of water and acidified by hydrochloric 
acid (1 N in water) to pH =2. White precipitate was extracted out with CH2Cl2 (2 x 20 mL). 
Combined organic fractions were washed by sat. NH4Cl, dried over Na2SO4, filtered, and 
concentrated in vacuo.  
      The carboxylic acid was then dissolved in 10 mL of CH3CN and cooled to 0 ⁰C. To this 
solution diisopropylethylamine (DIPEA, 239 mg, 1.85 mmol) was added dropwise. HBTU (367 
mg, 0.97 mmol) in 4 mL of CH3CN was added one portion followed by the slow addition of 1-
aminopiperidine (97 mg, 0.97 mmol). After the addition was complete, cold bath was removed 
and the reaction was stirred at room temperature for 16 hours. The mixture was then partitioned 
between 5% NaHCO3 (20 mL) + CH2Cl2 (50 mL). The organic fraction was separated and the 
aqueous fraction was extracted with CH2Cl2 (2 x 30 mL). Combined organic portions were 
washed by sat. NaCl, filtered, and concentrated in vacuo. The residue was purified by a column 
chromatography (SiO2, eluting with EtOAc/hexanes = 1:3) affording 22b (344 mg, 0.82 mmol, 
94%) as a white solid. Rf = 0.25 (EtOAc/hexanes = 1:2). Mp: 172-173 ⁰C. 1H NMR (400 MHz, 
CDCl3) δ 9.61 (s, 1H), 7.59-7.34 (m, 8H), 2.78 (t, 4H), 1.58-1.53 (m, 4H), 1.36-1.32 (m, 2H).  
13C NMR (CDCl3) δ157.3, 138.2, 138.1, 136.2, 135.7, 134.2, 132.0, 129.7, 128.5, 126.5, 123.4, 
56.9, 25.3, 23.2. Anal. Calcd for C20H19Cl2N5O : C, 57.70; H, 4.60; N, 16.82. Found: C, 57.66; H, 
4.68; N, 16.67. 
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      5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole Under N2, a solution of 2,4-
dichlorophenyl azide 24 (69 mg, 0.50 mmol) in 2 mL was added dropwise to ethyl magnesium 
chloride (0.25 mL, 2 M in THF). Stirring was continued at 50 ⁰C for 1 h. Then a solution of 
freshly made 2,4-dichlorophenyl azide (94 mg, 0.50 mmol) in 1 mL of  THF was added dropwise. 
The mixture was stirred at room temperature for 2 hr. and then heated to 50 ⁰C for 1 hr. The 
reaction was cooled down to 0 ⁰C quenched with sat. NH4Cl (20 mL) and diluted with EtOAc 
(30 mL). The organic fraction was separated. The aqueous fraction was extracted with EtOAc 
(30 mL × 2). Combined organic fractions were washed with brine (30 mL), dried on anhydrous 
MgSO4, filtered, and concentrated in vacuo. The residue was purified by a flash chromatography 
(SiO2, EtOAc/Hexanes = 1/5) affording 29a (138 mg, 85%) as a light yellow solid. Mp: 140-141 
⁰C. 1H NMR (400 MHz, CDCl3) δ 8.28 (s, 1H), 7.96-7.28 (m, 7H). 13C NMR (CDCl3) δ 138.6, 
135.8, 137.4, 136.0, 133.2, 132.7, 132.6, 130.9, 130.3, 129.6, 129.2, 128.6, 124.9. Anal. Calcd 
for C14H8Cl3N3 : C, 51.80; H, 2.48; N, 12.95. Found: C, 51.80; H, 2.48; N, 12.79. 
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      Methyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (30a) 
Under N2, a solution of 2,4-dichlorophenyl azide (205 mg, 1.50 mmol) in 2 mL was added 
dropwise to ethyl magnesium chloride (0.75 mL, 2 M in THF). Stirring was continued at 50 ⁰C 
for 1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (282 mg, 1.60 mmol) in 2 mL 
THF was added dropwise. The mixture was stirred at room temperature for 2 hr. and then heated 
to 50 ⁰C for 1 hr. The solution was cooled down to room temperature and added dropwise to the 
solution of methyl Chloroformate (184 mg,1.95 mmol) in 5 mL THF at -20⁰C. After stirring for 
10 minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
EtOAc/Hexanes = 1/5) affording 30a (0.35 g, 61%). Rf = 0.28 (EtOAc/Hexanes = 1:4). Mp: 158-
160 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.93-7.40 (m, 7H), 3.78 (s, 3H). 13C NMR (CDCl3) δ 
142.0, 137.9, 136.9, 136.3, 132.8, 132.1, 131.4, 130.8, 130.4, 129.0, 128.5, 123.3, 52.5. Anal. 
Calcd for C16H10Cl3N3O2 : C, 50.22; H, 2.63; N, 10.98. Found: C, 49.95; H, 2.68; N, 10.70. 
 
 
      5-(4-Chlorophenyl)-1-(2,4-dichlorophenyl)-N-(piperidin-1-yl)-1H-1,2,3-triazole-4-
carboxamide (22a) Methyl ester 30a (210 mg, 0.55 mmol) was taken up in KOH (45 wt% in 
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water, 2 mL) + 20 mL MeOH and heated to reflux for 2 hours. The reaction was cooled to room 
temperature and concentrated in vacuo. The residue was dissolved in 3 mL of water and acidified 
by hydrochloric acid (1 N in water) to pH =2. White precipitate was extracted out with CH2Cl2 (2 
x 20 mL). Combined organic fractions were washed by sat. NH4Cl, dried over Na2SO4, filtered, 
and concentrated in vacuo.  
      The carboxylic acid was then dissolved in 10 mL of CH3CN and cooled to 0 ⁰C. To this 
solution diisopropylethylamine (DIPEA, 149 mg, 1.16 mmol) was added dropwise. HBTU (227 
mg, 0.61 mmol) in 4 mL of CH3CN was added one portion followed by the slow addition of 1-
aminopiperidine (61 mg, 0.61 mmol). After the addition was complete, cold bath was removed 
and the reaction was stirred at room temperature for 16 hours. The mixture was then partitioned 
between 5% NaHCO3 (20 mL) + CH2Cl2 (50 mL). The organic fraction was separated and the 
aqueous fraction was extracted with CH2Cl2 (2 x 30 mL). Combined organic portions were 
washed by sat. NaCl, filtered, and concentrated in vacuo. The residue was purified by a column 
chromatography (SiO2, eluting with EtOAc/hexanes = 1:3) affording 30a (234 mg, 0.52 mmol, 
94%) as a white solid. Rf = 0.2 (EtOAc/hexanes = 1:3). Mp: 209-212 ⁰C. 1H NMR (400 MHz, 
CDCl3) δ 9.66 (s, 1H), 7.88-7.31 (m, 7H), 2.78 (t, 4H), 1.55-1.52 (m, 4H), 1.35-1.31 (m, 2H).  
13C NMR (CDCl3) δ157.2, 140.1, 137.5, 137.3, 136.2, 132.5, 132.2, 131.6, 130.6, 130.5, 129.7, 
128.4, 128.3, 123.1, 56.9, 25.4, 23.2. Anal. Calcd for C20H18Cl3N5O : C, 53.29; H, 4.03; N, 15.54. 
Found: C, 53.01; H, 4.10; N, 15.30. 
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      Ethyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (32a) 
Under N2, a solution of 1-chloro-4-ethynyl-benzene (232 mg, 1.70 mmol) in 2 mL was added 
dropwise to ethyl magnesium chloride (0.85 mL, 2 M in THF). Stirring was continued at 50 ⁰C 
for 1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (320 mg, 1.70 mmol) in 2 mL 
THF was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 
50 ⁰C for 1 hr. The reaction mixture was cooled down to room temperature and added dropwise 
to the solution of ethyl chloroformate (221 mg,2.04 mmol) in 5 mL THF at -20 ⁰C. After stirring 
for 10 minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 
mL). The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 
mL ×  2). Combined organic fractions were washed with brine (30 mL), dried on anhydrous 
MgSO4, filtered, and concentrated in vacuo. The residue was purified by a flash chromatography 
(SiO2, EtOAc/Hexanes = 1/5) affording 32 (370 mg, 55%) as a white solid. Mp: 135-136 ⁰C. Rf 
= 0.5 (Acetone: CHCl3:hexanes = 1:4:5). Mp: 135-136 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.94-
7.36 (m, 7H), 4.246 (q, 2H), 1.167 (t, 3H). 13C NMR (CDCl3) δ 160.9, 137.9, 136.9, 133.0, 132.2, 
132.4, 130.8, 130.4, 129.0, 128.5, 123.5, 61.7, 14.4. Anal. Calcd for C17H12Cl3N3O2 : C, 51.48; H, 
3.05; N, 10.59. Found: C, 51.75; H, 3.07; N, 10.66. 
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      Propyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (33) 
Under N2, a solution of 1-chloro-4-ethynyl-benzene (109 mg, 0.8 mmol) in 2 mL was added 
dropwise to ethyl magnesium chloride (0.4 mL, 2 M in THF). Stirring was continued at 50 ⁰C for 
1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (75 mg, 0.4 mmol) in 2 mL THF 
was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 50 ⁰C 
for 1 hr. The solution was cooled down to room temperature and added dropwise to the solution 
of propyl chloroformate (63.4 mg, 0.52 mmol) in 5 mL THF at -20⁰C. After stirring for 10 
minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by running a flash chromatography 
(SiO2, EtOAc/Hexanes = 1/5) affording 33 (93.4 mg, 57%). Rf = 0.3 (EtOAc/Hexanes = 1:5). Mp: 
117-118 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.92-7.39 (m, 7H), 4.145 (t, 2H), 1.539 (m, 2H), 
0.747 (t, 3H). 13C NMR (CDCl3) δ 160.9, 141.8, 137.8, 136.7, 136.6, 132.8, 132.1, 131.4 130.7, 
130.4, 128.9, 128.4, 123.6, 67.2, 22.0, 10.4. Anal. Calcd for C18H14Cl3N3O2 : C, 52.62; H, 3.44; 
N, 10.23. Found: C, 52.90; H, 3.47; N, 10.25. 
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      Butyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (34) 
Under N2, a solution of  1-chloro-4-ethynyl-benzene (68 mg, 0.5 mmol) in 2 mL was added 
dropwise to Ethyl magnesium chloride (0.25 mL, 2 M in THF). Stirring was continued at 50 ⁰C 
for 1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (94 mg, 0.5 mmol) in 1 mL 
THF was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 
50 ⁰C for 1 hr. The solution was cooled down to room temperature and added dropwise to the 
solution of butyl chloroformate (88 mg, 0.65 mmol) in 5 mL THF at -20⁰C. After stirring for 10 
minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
eluting with EtOAc/Hexanes = 1:5) affording 34 (127 mg, 60%) as a white solid. Rf = 0.34 
(EtOAc/Hexanes = 1:4). Mp: 108-111 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.92-7.39 (m, 7H), 
4.17 (t, 2H), 1.48 (m, 2H), 1.10 (m, 2H), 0.80 (t, 3H). 13C NMR (CDCl3) δ 160.9, 141.8, 137.8, 
136.7, 132.8, 132.1, 131.4 130.7, 130.4, 128.9, 128.4, 123.6, 65.5, 30.6, 19.2, 13.8. Anal. Calcd 
for C19H16Cl3N3O2 : C, 53.73; H, 3.80; N, 9.89. Found: C, 53.95; H, 3.81; N, 9.89. 
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      Hexyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (35) 
Under N2, a solution of 1-chloro-4-ethynyl-benzene (82 mg, 0.6 mmol) in 2 mL was added 
dropwise to Ethyl magnesium chloride (0.30 mL, 2 M in THF). Stirring was continued at 50 ⁰C 
for 1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (113 mg, 0.60 mmol) in 2 mL 
THF was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 
50 ⁰C for 1 hr. The solution was cooled down to room temperature and added dropwise to the 
solution of hexyl chloroformate (129 mg, 0.78 mmol) in 5 mL THF at -20 ⁰C. After stirring for 
10 minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
eluting with EtOAc/Hexanes = 1:5) affording 35 (163 mg, 60%) as a white solid. Rf = 0.33 
(EtOAc/Hexanes = 1:5). Mp: 89-91 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.92-7.39 (m, 7H), 4.16 (t, 
2H), 1.47 (m, 2H), 1.22-1.02 (m, 6H), 0.83 (t, 3H). 13C NMR (CDCl3) δ 160.9, 141.8, 137.8, 
136.8, 135.4, 132.8, 132.1, 131.4 130.7, 130.4, 128.9, 128.4, 123.6, 65.8, 31.6, 28.6, 25.7, 22.7, 
14.1. Anal. Calcd for C21H20Cl3N3O2 : C, 55.71; H, 4.45; N, 9.28. Found: C, 55.62; H, 4.52; N, 
9.06. 
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      Phenyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate Under 
N2, a solution of 1-chloro-4-ethynyl-benzene (150 mg, 1.10 mmol) in 2 mL was added dropwise 
to ethyl magnesium chloride (0.55 mL, 2 M in THF). Stirring was continued at 50 ⁰C for 1 hr. 
Then a solution of freshly made 2,4-dichlorophenyl azide (207 mg, 1.10 mmol) in 2 mL THF 
was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 50 ⁰C 
for 1 hr. The solution was cooled down to room temperature and added dropwise to the solution 
of phenyl chloroformate (206 mg,1.43 mmol) in 5 mL THF at -20⁰C. After stirring for 10 
minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
eluting with EtOAc/Hexanes = 1:4) affording phenyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-
1H-1,2,3-triazole-4-carboxylate (352 mg, 72%). Rf = 0.29 (EtOAc/Hexanes = 1:4). Mp: 205-208 
⁰C. 1H NMR (400 MHz, CDCl3) δ 7.96-7.21 (m, 12H). 13C NMR (CDCl3) δ 169.4, 150.4, 142.9, 
138.0, 137.0, 135.9, 132.8, 132.0, 131.4, 130.8, 130.4, 129.7, 129.0, 128.6, 126.4, 123.1, 121.7. 
Anal. Calcd for C21H12Cl3N3O2 : C, 56.72; H, 2.72; N, 9.45. Found: C, 55.57; H, 2.79; N, 9.47. 
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      Benzyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate (37) 
Under N2, a solution of 1-chloro-4-ethynyl-benzene (41 mg, 0.3 mmol) in 2 mL was added 
dropwise to Ethyl magnesium chloride (0.15 mL, 2 M in THF). Stirring was continued at 50 ⁰C 
for 1 hr. Then a solution of freshly made 2,4-dichlorophenyl azide (56 mg, 0.3 mmol) in 2 mL 
THF was added by dropwise. The mixture was heated at room temperature for 2 hr. and then at 
50 ⁰C for 1 hr. The solution was cooled down to room temperature and added dropwise to the 
solution of benzyl chloroformate (67 mg, 0.39 mmol) in 5 mL THF at -20⁰C. After stirring for 10 
minutes, the reaction was quenched with sat. NH4Cl (20 mL) and diluted with EtOAc (30 mL). 
The organic fraction was separated. The aqueous fraction was extracted with EtOAc (30 mL × 2). 
Combined organic fractions were washed with brine (30 mL), dried on anhydrous MgSO4, 
filtered, and concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
eluting with EtOAc/CH2Cl2/hexanes = 1:4:5) affording 37 (105 mg, 76%) as a white solid. Rf = 
0.43 (EtOAc/CH2Cl2/hexanes = 1:4:5). Mp: 148-151 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.91-
7.21 (m, 12H), 5.27 (s, 2H). 13C NMR (CDCl3) δ 160.6, 142.0, 137.8, 136.7, 136.5, 135.2, 132.8, 
132.0, 131.3, 130.7, 130.3, 128.9, 128.7, 128.6, 128.5, 128.4, 123.4, 67.1. Anal. Calcd for 
C22H14Cl3N3O2 : C, 57.64; H, 3.08; N, 9.16. Found: C, 57.84; H, 3.21; N, 9.08. 
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      Cyclohexyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-carboxylate 
(38) A flame dried 50-mL round bottomed flask was vacuumed and backfilled with N2. The flask 
was charged with cyclohexanol (20 mg, 0.2 mmol) in 10 mL of anhydrous THF. The solution 
was cooled to 0 ⁰C and n-butyl lithium (2.5 M in hexanes, 0.18 mmol) was added slowly. After 
stirring for 10 minutes, methyl 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-1H-1,2,3-triazole-4-
carboxylate (77 mg, 0.2 mmol) in 2 mL of anhydrous THF was added dropwise. The resultant 
solution was stirred for 1 hour and poured into 30 mL ice water in a separatory funnel and 
extracted with EtOAc (2 x 30 mL). The combined organic fractions were washed by sat. NaCl, 
dried on anhydrous MgSO4, filtered, and purified by running through a thin pad of silica gel. The 
solution was concentrated in vacuo affording 38 (89 mg, 99%) as a white solid. Mp: 138-141 ⁰C. 
1H NMR (400 MHz, CDCl3) δ 7.92-7.40 (m, 7H), 4.89 (m, 1 H), 1.73 (m, 1H), 1.42-1.17 (m, 
8H). 13C NMR (CDCl3) δ 160.3, 141.6, 137.8, 137.1, 136.7, 132.9, 132.2, 131.4, 130.8, 130.4, 
128.9, 128.4, 123.8, 74.4, 31.6, 25.3, 23.8. Anal. Calcd for C21H18Cl3N3O2 : C, 55.96; H, 4.03; N, 
9.32. Found: C, 55.96; H, 3.98; N, 9.22. 
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      2-Azido-1,1-diethoxyethane (41) A 50-mL round-bottomed flask was charged with 2-
bromo-1,1-diethoxyethane (1.97 g, 10 mmol) in 15 mL of DMSO. Sodium azide (1.95 g, 30 
mmol) was added. The reaction was heated to 100 ⁰C for 2 hours until the starting material spot 
disappeared on TLC. The reaction was cooled to room temperature, poured into 20 mL of ice 
water, and extracted with CH2Cl2 (2 x 50 mL). Combined organic fractions were washed by sat. 
NaCl (3 x 30 mL), dried on anhydrous Na2SO4, filtered, and concentrated in vacuo affording 41 
(1.55 g, 97%) as a slightly yellowish oil. Rf = 0.2 (EtOAc/hexanes = 1:4).  
 
 
      5-(4-Chlorophenyl)-1-(2,2-diethoxyethyl)-4-iodo-1H-1,2,3-triazole (42) A flame dried 
flash was filled with N2 and charged with 1-chloro-4-ethynylbenzene (0.82 g, 6 mmol) in 10 mL 
of anhydrous THF. At room temperature ethylmagnesium chloride (2 M in THF, 3 mL) was 
added slowly. The reaction was stirred at room temperature for 1 hour before 2-azido-1,1-
diethoxyethane (1.05 g, 6.6 mmol) in 3 mL of THF was added dropwise. The reaction was 
heated to 55 ⁰C for 2 hours. Iodine (1.82 g, 7.2 mmol) in 4 mL of THF was added and stirring 
continued for 10 minutes. The reaction was cooled to room temperature and quenched by the 
addition of 10 mL of sat. NH4Cl aqueous solution. The reaction mixture was partitioned between 
Na2S2O3 solution (2 N in water, 20 mL) and EtOAc (50 mL). The organic fraction was separated. 
The aqueous layer was extracted with EtOAc (2 x 30 mL). Combined organic fractions were 
washed by sat. NaCl, dried on anhydrous Na2SO4, filtered, and concentrated in vacuo. The 
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residue was purified on a flash chromatography (SiO2, eluting with EtOAc/hexanes = 1:4) 
affording 42 (1.99 g, 4.7 mmol, 79%) as a yellowish oil. Rf = 0.4 (EtOAc/hexanes = 1:4). 1H 
NMR (400 MHz, CDCl3) δ 7.51-7.39 (m, 4H), 4.82 (t, 1H), 4.33 (d, 2H), 3.35 (t, 4H), 1.03 (q, 
6H). 13C NMR (CDCl3) δ 140.2, 136.6, 131.7, 129.6, 124.6, 103.2, 90.2, 63.0, 55.8, 50.7, 16.1. 
 
 
      5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-(2,2-diethoxyethyl)-1H-1,2,3-triazole (43) 
42 (211 mg, 0.5 mmol), 2,4-dichlorophenyl boronic acid (105 mg, 0.55 mmol), Pd2(dba)3 (23 mg,  
0.025 mmol), tricyclohexylphosphine (17 mg, 0.06 mmol), and K3PO4 (180 mg, 0.85 mmol)were 
suspended in 8 mL THF + 2 mL H2O in a 30 mL pressure tube. The reaction vessel was purged 
with N2, sealed, and heated to 120 ⁰C for 16 hours in a oil bath. The reaction mixture was 
partitioned between water (40 mL) and EtOAc (40 mL). The organic layer was separated and the 
aqueous layer was extracted with EtOAc (2 x 40 mL). Combined organic fractions were washed 
by sat. NaCl, dried on anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
purified by a flash chromatography (SiO2, eluting with EtOAc/Hexanes = 1:3) affording 43 (216 
mg, 0.49 mmol, 98%). 1H NMR (400 MHz, CDCl3) δ 13C NMR (CDCl3) δ 7.53-7.30 (m, 7H), 
4.81 (t, 1H), 4.30 (d, 2H), 3.35 (t, 4H), 1.02 (q, 6H).  
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      2-(5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)acetaldehyde Under 
N2, 43 (661 mg, 1.5 mmol) was taken up in anhydrous chloroform (20 mL). Iodotrimethylsilane 
(360 mg, 0.245 mL, 1.8 mmol) was added to the solution and the reaction was stirred at room 
temperature for 1hours. Solvent was removed in vacuo and the residue was purified on a flash 
chromatography (SiO2, EtOAc/Hexanes = 1:1) affording 44 (297 mg, 0.81 mmol) with 30% of 
starting material recovered. 1H NMR (400 MHz, CDCl3) δ 9.75 (S, 1H), 7.53-7.30 (m, 7H), 5.54 
(s, 2H). 13C NMR (CDCl3) δ 192.8, 142.7, 136.5, 135.7, 134.6, 133.1, 131.3, 131.2, 130.5, 130.0, 
129.9, 129.6, 129.5, 128.0, 127.5, 124.7, 57.3.   
 
 
      (Z)-5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-(hex-2-enyl)-1H-1,2,3-triazole (45) A 
oven dried 25-mL round bottomed flask was flushed with N2 and charged with 
Ph3P(Br)(CH2)3CH3 (186 mg, 0.47 mmol) in 5 mL of anhydrous THF. At 0 ⁰C, t-BuOK (1 M in 
THF, 0.47 mL) was added dropwise. To the resultant bright orange solution was slowly added 44 
(114 mg, 0.31 mmol) dissolved in 1 mL of THF. The reaction was warmed up to room 
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temperature and stirred for 1 hour before sat. NH4Cl was added to quench the reaction. The 
reaction mixture was taken up in water (30 mL) + EtOAc (30 mL). The organic layer was 
separated and the aqueous layer was extracted with EtOAc (2 x 30 mL). Combined organic 
portions were washed by sat. NaCl, dried on MgSO4, filtered, and concentrated in vacuo. The 
residue was purified on a flash chromatography (SiO2, EtOAc/hexanes = 1:6) affording 45 (93 
mg, 74%) as a clear oil. Mp: 143-146 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.52-7.36 (m, 7H), 
5.62-5.49 (m, 2H), 5.12 (d, 2H), 2.05 (m, 1H), 1.98 (q, 1H), 1.34 (m, 2H), 0.85 (t, 3H). 13C NMR 
(CDCl3) δ 142.5, 135.9, 135.3, 135.2, 134.6, 133.2, 130.7, 129.9, 129.6, 129.5, 128.7, 127.4, 
125.9, 123.1, 46.4, 29.6, 22.4, 13.8.  
Anal. Calcd for C20H18Cl3N3 : C, 59.06; H, 4.46; N, 10.33. Found: C, 58.52; H, 4.54; N, 10.02. 
 
      5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-hexyl-1H-1,2,3-triazole (46) A 25-mL 
round-bottomed flask was charged with 45 (81 mg, 0.2 mmol). The flask was vacuumed and 
backfilled with H2. 10 wt.% Pd on activated carbon (8 mg) and 10 mL MeOH was added. The 
reaction was stirred at room temperature for 4 hours. The reaction solution was filtered through a 
thin pad of celite and washed with 20 mL of EtOAc and concentrated in vacuo. The residue was 
purified by a flash chromatography (SiO2, EtOAc/hexanes = 1:7) affording 46 (76 mg, 0.18 
mmol, 93%) as a clear oil. 1H NMR (400 MHz, CDCl3) δ 7.65-7.32 (m, 7H), 4.26 (t, 2H), 1.76 
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(m, 2H), 1.29-1.17 (m, 6H), 0.82 (t, 3H). 13C NMR (CDCl3) δ 143.6, 136.4, 133.9, 131.5, 131.4, 
130.1, 129.9, 129.4, 128.9, 128.8, 128.7, 128.2, 126.5, 48.6, 31.2, 30.2, 26.2, 22.5, 14.1. 
 
      1-Allyl-5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazole (47) A oven dried 50-
mL round-bottomed flask was charged with Ph3(Br)CH3 (157 mg, 0.44 mmol) in 10 mL 
anhydrous THF. At 0 ⁰C, t-BuOK (1 M in THF, 0.44 mL) was added dropwise. To the resultant 
bright orange solution was slowly added 44 (107 mg, 0.29 mmol) dissolved in 1 mL of THF. The 
reaction was warmed up to room temperature and stirred for 1 hour before sat. NH4Cl was added 
to quench the reaction. The reaction mixture was taken up in water (30 mL) + EtOAc (30 mL). 
The organic layer was separated and the aqueous layer was extracted with EtOAc (2 x 30 mL). 
Combined organic portions were washed by sat. NaCl, dried on MgSO4, filtered, and 
concentrated in vacuo. The residue was purified on a flash chromatography (SiO2, eluting with 
EtOAc/hexanes = 1:4) affording 47 (88 mg, 0.24 mmol, 83%) as a clear oil. Rf = 0.3 
(EtOAc/hexanes = 1:4). 1H NMR (400 MHz, CDCl3) δ 7.38-7.11 (m, 7H), 6.06-5.86 (m, 1H), 
5.28 (dd, J = 24, JJ = 1, 1H), 5.05 (dd, J = 41, JJ = 2, 1H), 4.96-4.94 (m, 2H). 13C NMR (CDCl3) 
δ 136.1, 135.5, 134.6, 133.2, 132.0, 130.6, 130.0, 129.6, 129.1, 128.6, 128.3, 127.4, 125.6, 119.2, 
51.1. 
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      5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-propyl-1H-1,2,3-triazole (48) A 25-mL 
round-bottomed flask was charged with 47 (80 mg, 0.22 mmol). The flask was vacuumed and 
backfilled with H2. 10 wt.% Pd on activated carbon (8 mg) and 10 mL MeOH was added. The 
reaction was stirred at room temperature for 4 hours. The reaction solution was filtered through a 
thin pad of celite and washed with 20 mL of EtOAc and concentrated in vacuo. The residue was 
purified by a flash chromatography (SiO2, EtOAc/hexanes = 1:6) affording 48 (77 mg, 0.21 
mmol, 97%) as a clear oil. Mp: 132 ⁰C. 1H NMR (400 MHz, CDCl3) δ 7.52-7.38 (m, 7H), 4.39 (t, 
2H), 1.84 (m, 2H), 0.85 (t, 3H). 13C NMR (CDCl3) δ 142.5, 135.9, 135.3, 134.9, 134.7, 133.2, 
131.4, 130.6, 130.1, 129.9, 129.7, 128.9, 128.8, 128.2, 127.4, 126.0, 50.5, 23.6, 11.2. Anal. 
Calcd for C17H14Cl3N3: C, 55.69; H, 3.85; N, 11.46. Found: C, 55.77; H, 3.85; N, 11.16.  
 
      Methyl 2-(5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)acetate (49) 
44 (135 mg, 0.37 mmol) was taken up in 4 mL acetone followed by the  addition of 2-methyl-2-
butene (0.15 mL). At 0 ⁰C, to this solution was added a solution of NaClO2 (262 mg, 2.9 mmol) 
+ NaH2PO4 (348 mg, 2.9 mmol). The reaction was stirred at room temperature for 1 hour. 
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Solvent was removed under reduced pressure. The residue was dissolved 1 N hydrochloric acid 
(5 mL) and extracted with CH2Cl2 (2 x 20 mL). Combined organic fractions were washed with 
sat. NaCl, dried on anhydrous Na2SO4, filtered, and concentrated affording the carboxylic acid 
49 (141 mg, 99%) as a white solid.  
      The carboxylic acid prepared above was dissolved in 3 mL toluene + 0.6 mL MeOH. At 0 ⁰C, 
TMSCHN2 (2 M in hexanes, 0.19 mL) was added dropwise. The reaction stirred at room 
temperature until the evolution of gas was ceased. The solvent was removed under reduced 
pressure. The residue was taken up in water (20 mL) + CH2Cl2 (20 mL). The organic layer was 
separated. The aqueous layer was extracted with (20 mL). Combined organic layers were washed 
by sat. NaCl, dried on anhydrous Na2SO4, filtered, and concentrated in vacuo. The residue was 
purified by a flash chromatography (SiO2, EtOAc:hexanes = 1:3) affording 50 (147mg, 93%) as 
a white solid. Mp: 145-146 ⁰C. Anal. Calcd for C17H12Cl3N3O2: C, 51.48; H, 3.05; N, 10.59. 
Found: C, 51.64; H, 3.15; N, 10.39. 
 
      2-(5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazol-1-yl)ethanol (51) 
Aldehyde 44 (204 mg, 0.56 mmol) was dissolved in 15 mL MeOH. At 0 ⁰C, NaBH4 (21 mg, 1.2 
mmol) was added by three portions. After stirring for 10 minutes, reaction was warmed to room 
temperature and continued stirring for 30 minutes. The solvent was removed and residue was 
taken up in sat. NH4Cl (aqueous, 20 mL) + CH2Cl2 (20 mL). The aqueous layer was extracted 
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with CH2Cl2 (2 x 20 mL). Combined organic portions were washed by sat. NaCl, dried on 
Na2SO4, filtered, and concentrated in vacuo. The residue was purified by a flash chromatography 
(SiO2, EtOAc/hexanes = 1:1) affording 51 (196 mg, 95%) as a clear oil. 1H NMR (400 MHz, 
acetone-d6) δ 7.50-7.40 (m, 7H), 4.48 (t, 2H), 4.04 (t, 2H), 1.96 (s, 1H). 13C NMR (CDCl3) δ 
142.0, 136.1, 136.0, 135.4, 134.5, 133.0, 131.0, 129.9, 129.5, 128.2, 127.3, 125.2, 60.8, 50.9. 
Calcd for C16H12Cl3N3O: C, 52.13; H, 3.28; N, 11.40. Found: C, 51.98; H, 3.46; N, 10.95. 
 
 
      5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1-(2-fluoroethyl)-1H-1,2,3-triazole (52)  
(Diethylamino)sulfur trifluoride (DAST, 131 mg, 0.81 mmol) was taken up in 10 mL anhydrous 
CH2Cl2 and cooled to  -78 ⁰C. The solution of 51 (100 mg, 0.27 mmol) in 2 mL CH2Cl2 was 
added dropwise. Upon completion of addition, the reaction was warmed to room temperature and 
stirred overnight. The reaction mixture was then washed with sat. NaCl, dried on anhydrous 
MgSO4, filtered, and concentrated in vacuo. The residue was purified on a flash chromatography 
(SiO2, CH2Cl2/EtOAc/hexanes = 5:1:4) affording 52 (85 mg, 85%) as a white solid. Mp: 98-
103⁰C. 1H NMR (400 MHz, acetone-d6) δ 7.57-7.36 (m, 7H), 5.01-4.73 (m, 4H). 13C NMR 
(CDCl3) δ 136.2, 135.5, 134.7, 133.2, 131.1, 131.0, 130.0, 129.7, 128.5, 127.4, 125.3, 82.6, 80.8, 
48.9, 48.7. Calcd for C16H11Cl3FN3: C, 51.85; H, 2.99; N: 11.34. Found: C, 52.07; H, 2.81; N, 
11.25.  
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      1-(2-Chloroethyl)-5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazole (54) A 
10-mL round-bottomed flask was charged with a stirring bar and 1 mL of pyridine. 51 (75 mg, 
0.20 mmol) was added followed by the addition of TsCl (194 mg, 1.0 mmol). The reaction was 
stirred at room temperature for 30 minutes. The solvent pyridine was removed under reduced 
pressure. The residue was taken up in sat. NaHCO3 (5 mL) + CH2Cl2 (10 mL). The organic 
fraction was separated, dried on anhydrous MgSO4, filtered, and concentrated in vacuo. 
      Anhydrous LiCl (34 mg, 0.8 mmol) and the tosylate prepared from above were taken up in 
20 mL of absolute ethanol. The reaction was heated to reflux for 15 hours. The solvent was 
removed. The residue was dissolved in CH2Cl2 (10 mL), washed by sat. NaCl (10 mL), dried on 
anhydrous MgSO4, and concentrated in vacuo. The residue was purified on a flash 
chromatography (SiO2, eluting with EtOAc/hexanes = 1:8) affording 54 (56 mg, 72%). Rf = 0.5 
(EtOAc/hexanes = 1:6). 
 
 
      1-(2-Bromoethyl)-5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazole (55) A 10-
mL round-bottomed flask was charged with a stirring bar and 1 mL of pyridine. 51 (75 mg, 0.20 
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mmol) was added followed by the addition of TsCl (194 mg, 1.0 mmol). The reaction was stirred 
at room temperature for 30 minutes. The solvent pyridine was removed under reduced pressure. 
The residue was taken up in sat. NaHCO3 (5 mL) + CH2Cl2 (10 mL). The organic fraction was 
separated, dried on anhydrous MgSO4, filtered, and concentrated in vacuo. 
      Anhydrous LiBr (60 mg, 0.8 mmol) and the tosylate prepared from above were taken up in 
20 mL of anhydrous acetone. The suspension was heated to reflux for 15 hours. The solvent was 
removed. The residue was dissolved in CH2Cl2 (10 mL), washed by sat. NaCl (10 mL), dried on 
anhydrous MgSO4, and concentrated in vacuo. The residue was purified on a flash 
chromatography (SiO2, eluting with EtOAc/hexanes = 1:8) affording 55 (54 mg, 63%). Rf = 0.5 
(EtOAc/hexanes = 1:6). 
 
      1-Benzyl-5-(4-chlorophenyl)-4-iodo-1H-1,2,3-triazole (56) A flame dried flash was filled 
with N2 and charged with 1-chloro-4-ethynylbenzene (0.274 g, 2 mmol) in 5 mL of anhydrous 
THF. At room temperature ethylmagnesium chloride (2 M in THF, 1 mL) was added slowly. The 
reaction was stirred at room temperature for 1 hour before benzyl azide (293 mg, 0.25 mL, 2.2 
mmol) was added dropwise. The reaction was heated to 55 ⁰C for 2 hours. Iodine (1.82 g, 7.2 
mmol) in 2 mL of THF was added and stirring continued for 10 minutes. The reaction was 
cooled to room tempearature and quenched by the addition of 10 mL of sat. NH4Cl aqueous 
solution. The reaction mixture was partitioned between Na2S2O3 solution (2 N in water, 10 mL) 
and EtOAc (30 mL). The organic fraction was separated. The aqueous layer was extracted with 
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EtOAc (2 x 30 mL). Combined organic fractions were washed by sat. NaCl, dried on anhydrous 
Na2SO4, filtered, and concentrated in vacuo. The residue was purified on a flash chromatography 
(SiO2, eluting with EtOAc/hexanes = 1:6) affording 56 (554 mg, 70%) as a white solid.  
 
 
      1-Benzyl-5-(4-chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazole (57) 56 (829 mg, 2 
mmol), 2,4-dichlorophenyl boronic acid (420 mg, 2.2 mmol), Pd2(dba)3 (92 mg,  0.1 mmol), 
tricyclohexylphosphine (68 mg, 0.24 mmol), and K3PO4 (721 mg, 3.4 mmol) were suspended in 
16 mL THF + 4 mL H2O in a 50 mL pressure tube. The reaction vessel was purged with N2, 
sealed, and heated to 120 ⁰C for 16 hours in a oil bath. The reaction mixture was partitioned 
between water (40 mL) and EtOAc (40 mL). The organic layer was separated and the aqueous 
layer was extracted with EtOAc (2 x 40 mL). Combined organic fractions were washed by sat. 
NaCl, dried on anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified 
by a flash chromatography (SiO2, eluting with EtOAc/Hexanes = 1:4) affording 57 (827 mg, 
99%) as a white solid. Rf = 0.3 (EtOAc/Hexanes = 1:4). Mp: 146-149 ⁰C. 1H NMR (400 MHz, 
acetone-d6) δ 7.38-6.96 (m, 12H), 5.53 (s, 2H).13C NMR (CDCl3) δ 146.3, 135.8, 135.3, 135.2, 
134.5, 133.1, 130.6, 129.8, 129.4, 129.0, 128.5, 128.4, 127.3, 127.2, 125.5, 52.9. Calcd for 
C21H14Cl3N3: C, 60.82; H, 3.40; N, 10.13. Found: C, 60.53; H, 3.40; N, 9.89.  
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      5-(4-Chlorophenyl)-4-(2,4-dichlorophenyl)-1H-1,2,3-triazole (58) 57 (40 mg, 0.1 mmol) 
was dissolved in 0.5 mL anhydrous DMSO and 1.5 mL anhydrous THF and cooled to 0 ⁰C. To 
this solution was slowly added t-BuOK (1 M in THF, 1 mL). Upon the completion of addition, 
O2 was bubbled through the resultant dark blue mixture for 15 minutes until the blue color 
disappeared and TLC indicated no starting material remained. The reaction was portioned 
between sat. NaCl (20 mL) + CH2Cl2 (30 mL). The organic fraction was separated. The aqueous 
fraction was extracted with CH2Cl2 (2 x 20 mL). Combined organic portions were washed by sat. 
NaCl (30 mL), dried on anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was 
purified by a flash chromatography (SiO2, eluting with EtOAc/hexanes = 2:3) affording 58 (32 
mg, 99%) as a clear oil.  
 
 
      2-Benzyl-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazole (59) Under N2, 58 
(145 mg, 0.45 mmol) was dissolved in 2 mL anhydrous DMF. NaH (40% in mineral oil, 21.4 mg, 
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0.54 mmol) was added by one portion and stirred for 15 minutes at room temperature. Benzyl 
bromide (81 mg, 0.056 mL, 0.47 mmol) was added dropwise and stirred overnight. The reaction 
was then quenched with aqueous NH4Cl (1 N) and diluted with water (10 mL) + EtOAc (15 mL). 
The organic portion was separated. The aqueous portion was extracted with EtOAc (2 x 20 mL). 
Combined organic fractions were washed by sat. NaCl, dried on MgSO4, filtered, and 
concentrated in vacuo. The residue was purified on a flash chromatography (SiO2, eluting with 
EtOAc/hexanes = 1:3) affording 59 (112 mg, 60%) as a white solid. Rf = 0.4 (EtOAc/Hexanes = 
1:3). 1H NMR (400 MHz, acetone-d6) δ 7.66-7.37 (m, 12H), 5.75 (s, 2H). 13C NMR (CDCl3) δ 
144.9, 141.7, 135.9, 135.1, 134.5, 133.0, 130.1, 129.2, 129.0, 128.7, 128.6, 128.3, 127.6, 126.5, 
59.2. Calcd for C21H14Cl3N3: C, 60.82; H, 3.40; N, 10.13. Found: C, 60.97; H, 3.56; N, 9.92.  
 
      Butyl 4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazole-2-carboxylate (60)   
Under N2, 58 (94 mg, 0.29 mmol) was dissolved in 4 mL anhydrous THF. NaH (40% in mineral 
oil, 14 mg, 0.35 mmol) was added by one portion and stirred for 15 minutes at room temperature. 
The solution was then added dropwise to another flask that was charged with butyl 
chloroformate (48 mg, 0.35 mmol) in 2 mL anhydrous THF. The reaction was stirred at room 
temperature for 2 hours and quenched with aqueous NH4Cl (1 N) and diluted with water (10 mL) 
+ EtOAc (15 mL). The organic portion was separated. The aqueous portion was extracted with 
EtOAc (2 x 20 mL). Combined organic fractions were washed by sat. NaCl, dried on MgSO4, 
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filtered, and concentrated in vacuo affording 60 (123 mg, 0.29 mmol) as a white solid. 1H NMR 
(400 MHz, acetone-d6) δ 7.50-7.30 (m, 7H), 4.62 (t, 2H), 1.89 (m, 2H), 1.52 (m, 2H), 0.11 (t, 
3H). 13C NMR (CDCl3) δ 147.6, 136.9, 136.0, 135.0, 132.8, 130.2, 129.3, 128.8, 127.8, 127.6 
70.1, 30.6, 19.0, 13.8. Calcd for C19H16Cl3N3O2: C, 53.73; H, 3.80; N, 9.89. Found: C, 53.74; H, 
3.85; N, 9.77.  
 
      Methyl 2-(4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazol-2-yl)acetate (61) 
58 (200 mg, 0.62 mmol) was dissolved in 3 mL anhydrous DMF in a flask backfilled with N2. 
NaH (40% in mineral oil, 29.6 mg, 0.65 mmol) was added. The reaction was stirred at room 
temperature for 15 minutes before methyl 2-bromoacetate (99 mg, 0.65 mmol) was added 
dropwise. After stirring for 20 hours at room temperature, the reaction was quenched by 1 N 
NH4Cl in water (1 mL). The mixture was diluted with water (15 mL) + EtOAc (15 mL). The 
organic layer was separated. The aqueous layer was extracted with EtOAc (2 x 15 mL). 
Combined organic portions were washed with sat. NaCl, dried on MgSO4, filtered, and 
concentrated in vacuo. The residue was purified on a flash chromatography (SiO2, eluting with 
EtOAc/hexanes = 1:3) affording 61 (147 mg, 0.37 mmol, 60%). Rf = 0.47 (EtOAc/hexanes = 
1:3). Mp: 121-123 ⁰C. 1H NMR (400 MHz, acetone-d6) δ 7.67-7.39 (m, 7H), 5.47 (s, 2H), 3.79 
(s, 3H). 13C NMR (CDCl3)  δ 167.1, 145.7, 142.4, 136.1, 135.0, 134.7, 132.9, 130.2, 129.1, 129.0, 
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128.9, 128.3, 127.6, 55.8, 53.1. Calcd for C17H12Cl2N3O2: C, 51.48; H, 3.05; N, 10.59. Found: C, 
51.58; H, 3.05; N, 10.40.  
 
 
      4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-hexyl-2H-1,2,3-triazole (62) 58 (65 mg, 0.2 
mmol) was dissolved in 3 mL anhydrous DMF in a flask backfilled with N2. NaH (40% in 
mineral oil, 13.2 mg, 0.22 mmol) was added. The reaction was stirred at room temperature for 15 
minutes before hexyl bromide (41 mg, 0.25 mmol) was added dropwise. After stirring for 12 
hours at room temperature, the reaction was quenched by 1 N NH4Cl in water (1 mL). The 
mixture was diluted with water (10 mL) + EtOAc (10 mL). The organic layer was separated. The 
aqueous layer was extracted with EtOAc (2 x 10 mL). Combined organic portions were washed 
with sat. NaCl, dried on MgSO4, filtered, and concentrated in vacuo. The residue was purified on 
a flash chromatography (SiO2, eluting with EtOAc/hexanes = 1:8) affording 62 (49 mg, 60%) as 
a clear oil. 
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      4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-propyl-2H-1,2,3-triazole (63) 58 (88 mg, 
0.27 mmol) was dissolved in 3 mL anhydrous DMF in a flask backfilled with N2. NaH (40% in 
mineral oil, 18 mg, 0.3 mmol) was added. The reaction was stirred at room temperature for 15 
minutes before bromopropane (40 mg, 0.32 mmol) was added dropwise. After stirring for 12 
hours at room temperature, the reaction was quenched by 1 N NH4Cl in water (1 mL). The 
mixture was diluted with water (10 mL) + EtOAc (10 mL). The organic layer was separated. The 
aqueous layer was extracted with EtOAc (2 x 10 mL). Combined organic portions were washed 
with sat. NaCl, dried on MgSO4, filtered, and concentrated in vacuo. The residue was purified on 
a flash chromatography (SiO2, eluting with EtOAc/hexanes = 1:8) affording 63 (50 mg, 50%) as 
a yellowish oil. 
 
 
      2-(4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazol-2-yl)ethanol (64) Methyl 
ester 61 (320 mg, 0.81 mmol) was dissolved in 10 mL anhydrous THF. To the resultant solution 
LiAlH4 (2 M in THF, 1.22 mL) was added dropwise at -40 ⁰C. Upon the completion of addition, 
the reaction was brought up to 0 ⁰C and stirred for 15 minutes. The reaction was then quenched 
with 1 M NH4Cl in water (0.3 mL). After vigorously stirring for 5 minutes, anhydrous MgSO4 
was added and the slurry was filtered. The filtrate was concentrated in vacuo. The residue was 
purified by running through a short pad of silica gel affording 64 (298 mg, 99%) as a clear oil. Rf 
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= 0.36 (EtOAc/hexanes = 1:1). 1H NMR (400 MHz, acetone-d6) δ 7.67-7.36 (m, 7H), 4.59 (t, 
2H), 4.23 (s, 1H), 4.15 (t, 2H). 13C NMR (CDCl3)  δ 144.7, 143.7, 141.3, 135.9, 134.9, 134.7, 
134.5, 132.8, 130.1, 129.6, 129.1, 129.0, 128.9, 128.8, 128.7, 127.6, 60.9, 57.2.  
 
 
      4-(4-Chlorophenyl)-5-(2,4-dichlorophenyl)-2-(2-fluoroethyl)-2H-1,2,3-triazole (65) 
DAST (223 mg, 0.183 mL, 1.38 mmol) was taken up in 15 mL anhydrous CH2Cl2. At -78 ⁰C, 64 
(170 mg, 0.46 mmol) in 3 mL of CH2Cl2 was added to the DAST solution dropwise. After the 
addition was complete, the cold bath was removed and the reaction was brought up to room 
temperature and stirred overnight. The reaction mixture was washed by sat. NaCl (20 mL), dried 
on anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was purified on a flash 
chromatography (SiO2, EtOAc/hexanes = 1:4) affording 65 (140 mg, 82%) as a clear oil. Rf = 0.4 
(EtOAc/hexanes = 1:4). 1H NMR (400 MHz, acetone-d6) δ 7.65-7.36 (m, 7H), 5.11-4.80 (m, 4H). 
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      2-(2-Chloroethyl)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazole (66) 
Alcohol 64 (163 mg, 0.44 mmol), pyridine (168 mg, 0.88 mmol), and toluene sulphonyl chloride 
(70 mg, 0.88 mmol) were taken up in 5 mL of CH2Cl2 and stirred at room temperature for 4 
hours. The solvent was removed and the residue was purified by running through a thin pad of 
silica gel. The concentrate together with lithium chloride (186 mg, 4.4 mmol) was taken up in 20 
mL of absolute ethanol. The reaction was refluxed for 15 hours. The solvent was removed and 
the residue was dissolved in 20 mL water and extracted with EtOAc (2 x 20 mL). Combined 
organic portions were washed with sat. NaCl, dried on MgSO4, filtered, and concentrated in 
vacuo. The residue was purified on a flash chromatography (SiO2, EtOAc/hexanes = 1:6) 
affording 66 (153 mg, 90%) as a white solid. Mp: 115-118 ⁰C. Rf = 0.55 (EtOAc/hexanes = 1:4). 
1H NMR (400 MHz, acetone-d6) δ 7.52-7.27 (m, 7H), 4.81 (t, 2H), 4.08 (t, 2H). 13C NMR 
(CDCl3)  δ245.1, 141.9, 136.0, 135.1, 134.6, 132.9, 130.2, 129.7, 129.2, 129.1, 129.0, 128.3, 
127.7,56.3, 41.5.  
 
 
      2-(2-Bromoethyl)-4-(4-chlorophenyl)-5-(2,4-dichlorophenyl)-2H-1,2,3-triazole (67)  
Alcohol 64 (111 mg, 0.3 mmol), pyridine (114 mg, 0.6 mmol), and TsCl (48 mg, 0.6 mmol) were 
taken up in 5 mL of CH2Cl2 and stirred at room temperature for 4 hours. The solvent was 
removed and the residue was purified by running through a thin pad of silica gel. The 
concentrate together with LiBr (260 mg, 3 mmol) was taken up in 20 mL of acetone. The 
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reaction was refluxed for 15 hours. The solvent was removed and the residue was dissolved in 20 
mL water and extracted with EtOAc (2 x 20 mL). Combined organic portions were washed with 
sat. NaCl, dried on MgSO4, filtered, and concentrated in vacuo. The residue was purified on a 
flash chromatography (SiO2, EtOAc/hexanes = 1:6) affording 67 (102 mg, 79%) as a white solid. 
Rf = 0.5 (EtOAc/hexanes = 1:6). 
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CHAPTER 2 
SYNTHESIS OF PYRROLIDINE 225H AND A FORMAL SYNTHESIS OF  
(+)-GEPHYROTOXIN 
 
2.1 ABSTRACT 
 
       Neuronal nicotinic acetylcholine receptors have long been the target for the development of 
a large number of central nervous system diseases and disorders. In an effort to develop new 
neuronal nicotinic acetylcholine receptor ligands as therapeutic agents, we have been very 
interested in amphibian alkaloids. 
      To effectively synthesize amphibian alkaloids, our research group has recently developed a 
general synthetic strategy which can rapidly prepare a few amphibian alkaloids simply from the 
abundant natural product (-)-cocaine 1 as a starting material (Scheme 2.1). This strategy was first 
successfully applied to the synthesis of (-)-monomorine. More recently, this strategy has also 
been utilized in the syntheses of both of the enantiomers of cis-pyrrolidine 225H and (+)-
gephyrotoxin 287C. 
 
 
Scheme 2.1 Synthesis of amphibian from 2,5-cis-pyrrolidine building block 
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2.2 INTRODUCTION 
 
      Amphibians have produced a great number of biologically active compounds as a chemical 
defense against predators. These compounds are mostly present in the skin or venom of 
amphibians. Lipophilic alkaloids are one of the largest categories of chemicals detected in 
amphibian skin. Through 2005, over 800 hundred amphibian alkaloids of over 20 structural 
classes have been reviewed.1 The structural diversity and biological activity of amphibian 
alkaloids have aroused tremendous academic and pharmaceutical interest. However, the presence 
of alkaloids in amphibian species is very scarce. Dependence on the supply from natural sources 
is very limited. Therefore, total synthesis is the most used method to provide sufficient material 
for intensive structure and biological activity studies. An ongoing project in our laboratory has 
been to develop synthetic strategies for the construction of amphibian alkaloids that exhibit 
pharmacological activities mediated by nicotinic receptor ion channels.  
      Neuronal nicotinic acetylcholine receptors (nAChRs) are members of a super family of 
central nervous system synapses and the neuromuscular endplate. Neuronal nicotinic 
acetylcholine receptors respond to physiological signal of the neurotransmitter acetylcholine. 
They can also be activated by nicotine.2 Neuronal nicotinic acetylcholine receptors have been the 
target for the drug development for tobacco addiction, smoking cessation, muscle relaxation, and 
anti-hypertension.3,4 More recently, neuronal nicotinic acetylcholine receptors have been the 
target for the development of new therapeutic agents for the treatment of a number of other 
central nervous system disease and disorders such as Alzheimer’s Disease, Parkinson’s Disease, 
Tourettes syndrome, anxiety, and depression. Scientific findings have also indicated that nicotine 
receptors are involved in memories and learning activities. It is now widely believed that 
76 
 
neuronal nicotinic acetylcholine receptor agonists and antagonists have great potential for the 
treatment of a variety of diseases and disorders.  
      Unfortunately, most of the neuronal nicotinic acetylcholine receptor agents available up to 
date have adverse side effects which severely prevent them from being applied as drug therapy. 
Therefore, it is of great interest and benefit to discover and search novel nicotinic receptor 
ligands and develop them to provide therapeutic agents and medications for the treatment of a 
variety of neurological diseases and disorders. 
 
Figure 2.1 Structures of Amphibian Alkaloids and Cocaine 
 
       Several classes of the amphibian alkaloids have been found to be non-competitive blockers 
at nicotinic receptor ion channels. Among these alkaloids, at least four classes share the common 
skeletal structure. They are the pyrrolidine, pyrrolizidine, indolizidine, and gephyrotoxin. As 
illustrated in Figure 2.1, they are respectively represented by four natural products, (+)-
monomorine 4, cis-pyrrolidine 225H 5, trans-pyrrolizidine 223H 6 and (+)-gephyrotoxin 7. A 
cis-2,5-disubstituted pyrrolidine-ring structural feature was observed in all of those four natural 
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products. Meanwhile, this ring system can also be found in the abundant natural product (-)-
cocaine•HCl. Seeing this prominent similarity, we were encouraged to develop an 
enantioselective and general synthetic strategy preparing sample amphibian alkaloids and 
analogues for further structure-activity studies.  
 
 Pyrrolidine 225H 
 
 
 2,5-Pyr  R1  R2  
 183B  n-C4H9  n-C4H9  
 *197B  n-C4H9  n-C5H11  
trans  223N  C6H11  n-C5H11  
 225C  n-C4H9  n-C7H15  
 225H  n-C6H13 n-C5H11  
cis/trans  235F  C7H13  C5H9  
 253I  n-C6H13  n-C7H15  
trans  277D  C6H11  C9H17  
 279G  n-C6H13  n-C9H17  
 
Table 2.1 Pyrrolidines 
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      A 2,5-disubstituted pyrrolidine has been identified as the major alkaloid in skin extracts of 
Dendrobates histrionicus, a population of a Colombian dendrobatid frog. Such 2,5-disubstituted 
pyrrolidines (Table 2.1) were also detected in myrmicine ant venoms. These 2,5-disubstituted 
pyrrolidines were found to exhibit insecticidal activity serving as a defensive repellant.5 
Synthetic compound, 197B, acted as a noncompetitive blocker of nicotinic receptor exhibiting 
interesting biological activities.6 Yet very little is known about this class of alkaloids. Up to date, 
there is only one pyrrolidine structure was firmly established with organic synthesis as a tool. We 
were pleased to find that most of cis-2,5-disubstituted pyrrolidines in the chart can be 
synthesized from (-)-cocaine with two chiral centers directly introduced from  (-)-cocaine. We 
selected pyrrolidine 225H as an example to interpret the application of this strategy.  
      The only laboratory synthesis of unsymmetrical 2,5-pyrrolidines was reported about 30 years 
ago.7 As demonstrated in Scheme 2.2, a complexity of multiple isomers occurred in the reaction 
sequence as a result of harsh reaction conditions in the reaction sequences. 
 
 
Scheme 2.2 Review of the synthesis of Pyrrolidine 225H 
Reagents and conditions: a) PCC; b) R'CHO, Et3N; c) (NH4)2CO3; d) H2, Rh/Al2O3. 
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(+)-Gephyrotoxin 
      Four classes of tricyclic alkaloids have been detected in amphibians. Gephyrotoxin was the 
first tricyclic alkaloid that has been structurally defined. It was isolated from the skin secretion of 
tropical frog Dendrobates histrionicus and characterized by Daly and co-workers in 1977.8  
Although controversy still remains as to the absolute configuration of the major component from 
the Dendrobates histrionicus, this compound has aroused increasing pharmacological interest 
due to its observed biological activities. (+)-Gephyrotoxin was relatively nontoxic. It exhibited 
weak muscarinic antagonist activities and neurological activities. It acted as a noncompetitive 
blocker of nicotinic receptor-channels of muscle, electric ray electroplax, and 
pheochromocytoma cells.8 Due to its extreme scarcity in nature, (+)-Gephyrotoxin and analogues 
have been an interesting synthetic target for several organic synthetic groups.   
 
 
Scheme 2.3 Review of synthesis of Kishi’s Intermediate I 
Reagents and conditions: a) 1. P2S5, pyridine, 80 ⁰C; 2. MeCOCH(Br)CO2Et, NaHCO3, reflux; 3. 
0.1 N KOH, EtOH, 80 ⁰C; b) H2 (1 atm), 5 % Pd/C, HClO4, MeOH, rt; c) 1. C6H5OCOCl, 
pyridine, CH2Cl2, rt; 2. LiBH4, THF, rt; 3. KH, THF, rt; d) 1. DIBAL-H, THF/toluene, -105 ⁰C; 
2. 3 N HCl; 3. NaBH4, DME, rt; 4. MeOCH2Br, DIPEA, CH2Cl2, rt; 5. Ba(OH)2, H2O, reflux. 
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      Among the different approaches, only one total synthesis and two formal syntheses have 
been reported for the enantioselective preparation of (+)-Gephyrotoxin. The first and only 
enantioselective total synthesis of (+)-Gephyrotoxin was reported by Kishi and coworkers.9 In 
their synthesis (Scheme 2.3), L-pyroglutamic acid was converted into the enantiopure cis-2,5-
disubstituted pyrrolidine 8 in 15 step and another 3 steps led to the tricyclic intermediate 9 which 
is called Kishi’s intermediate. Kishi’s intermediate is a tricyclic compound with two chiral 
centers and a cis-2,5-disubstituted pyrrolidine ring system. Kishi’s strategy provided Kishi’s 
intermediate in 18 steps from L-pyroglutamic acid and it included a hydrogenation step which 
afforded a 2.3:1 mixture of cis- and trans-pyrrolidine.  
 
Scheme 2.4 Review of synthesis of Kishi’s Intermediate II 
Reagents and conditions: a) TBDPSCl, imidazole; b) 1. toluene/EtOH, Na2SO4, piperidinium 
acetate, 100 ⁰C; 2. 5% Pd/C, H2 (1 atm), EtOAc/EtOH; c) TBAF, CH2Cl2, 0 ⁰C. 
 
      Hsung and coworkers reported a shorter access to Kishi’s intermediate (Scheme 2.4). The 
key step of Hsung’s strategy was the stereoselective intramolecular formal [3+3] cycloaddition 
reaction of vinylogous amide with α,β-unsaturated aldehyde 11 which was obtained by 
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condensation of the chiral amino diol 10 with 1,3-cyclo-hexanedione. This synthesis afforded 
Kishi’s intermediate in 10 steps from commercially available starting material. However the 
intramolecular cycloaddition gave the tricyclic precursor 12 in a low yield (50%) and a poor 
diastereoselectivity.10  
 
 
Scheme 2.5 Review of synthesis of Kishi’s Intermediate III 
Reagents and conditions: a) 1. LDA; 2. p-TsOH, DHP, CH2Cl2; b) Zn(ClO4)2•6H2O, MgSO4, 
CH2Cl2; c) 1. NaBH4, AcOH, CH3CN; 2. H2, Pd(OH)2/C, Boc2O, AcOMe; 3. LiAlH4, THF, 0 ⁰C; 
4. NaH, BnBr, TBAI, DMF; 5. HCl, MeOH; d) p-TsOH, toluene; e) 1. PBr3, CH2Cl2; 2. NaI, 
CH3CN; 3. H2, Pd/C, HClO4, MeOH. 
 
      More recently, Vanucci-Bacqué and coworkers reported a more diastereocontrolled synthesis 
of Kishi’s intermediate (Scheme 2.5). In this strategy, Vanucci-Bacqué synthesized the 
enantiopure cis-2,5-disubstituted pyrrolidine 15 from the diastereocontrolled reduction of the 
chiral bicyclic pyrrolidine β-enamino ester 14 which was obtained by condensation of the chiral 
amine (S)-phenylglycinol 13 on a protected ω-oxo β-keto ester 12.11 
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Scheme 2.6 Review of the synthesis of (+)-Gephyrotoxin from Kishi’s Intermediate 
Reagents and conditions: a) H2 (60 psi), 5% Pt/Al, EtOAc; b) (COCl)2, DMSO, Et3N, CH2Cl2; c) 
1.EtOCCMgCl, THF; 2.MeMgBr; 3. H3O+; 4. t-Bu(C6H5)2SiCl, imidazole; d) 1. H2 (1 atm), 5% 
Rh/Al2O3, hexanes; 2. LiAlH4; e) 1. PCC; 2. Ph3P(CH=CHOEt)Br; 3. TSA, acetone/H2O; f) 1. 
Ph3P(CH2Cl)Cl, BuLi, THF; 2. MeLi, Me3SiCl, THF; 3. TBAF, DMF. 
 
     As demonstrated in Scheme 2.6, Kishi’s intermediate was diastereoselectively converted into 
(+)-gephyrotoxin by Kishi et. al.12 The unique and key aspect of the synthesis was that all three 
remaining asymmetric centers on the tricylic ring were stereoselectively introduced through 
hydrogenation reactions with specific catalysts and additives. When the hydrogenation of the 
vinylogous amide 8 was carried out with the presence of 10% Pd/C in ethyl acetate under 60 psi 
hydrogen pressure, the hydrogenation product along with hydrogenolysis side product were 
found to be the product with reversed stereochemical outcome. However, when the reaction 
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proceeded using 5% Platinum on an alumina support in anhydrous ethyl acetate at 60 psi 
hydrogen pressure at room temperature, the desired product 16 was obtained with the best result 
of a 12:1 ratio of the amino alcohol favoring the product with the right asymmetrical centers. For 
the purpose of purification and protection, the amino alcohol was isolated as its monoacetate. 
Swern oxidation of the alcohol 16 gave the ketone 17 which reacted with 
ethoxyacetylenemagnesium chloride in THF giving a mixture of the Z and E isomers 18. 
Addition of methylmagnesium bromide to the acetate ester and acid workup followed by the 
silylation afforded the unsaturated ester 19. The introduction of the bulky silyl group 
dramatically controlled the stereoselectivity of the last hydrogenation. With the directing effect 
of the silyl group, dissolving metal reduction by lithium in liquid ammonium followed by lithium 
aluminum hydride reduction gave the equatorial isomer with a 35:1 selectivity disfavoring the 
desired product. On the other hand, hydrogenation with 5% Rhodium on Al2O3 support in 
hexanes with 1 atm hydrogen atmosphere followed by lithium aluminum hydride reduction gave 
the axial isomer favoring the desired product with a 10:1 ratio. The stereochemistry of this 
synthesis was further proved by the comparison of the synthetic compound with authentic 
sample derived from natural source.   
 
2.3 RESULTS AND DISCUSSION 
 
Synthesis of (-)-Monomorine 
      As discussed earlier, (+)-monomorine 3, cis-pyrrolidine 225H 4, pyrrilizidine 233H 5 and 
(+)-gephyrotoxin 6 all share the common structural feature of a cis-2,5-disubstituted pyrrolidine 
ring system. This structural similarity encouraged us to develop a general synthetic sequence to 
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enantioselectively prepare those natural products. The building block in this strategy is cis-2,5-
disubstituted pyrrolidine 2 which can be easily obtained from (+)-2-tropinone 22. (+)-2-
Tropinone 22 was selected as the early stage intermediate due to its availability and relative ease 
of preparation in our research laboratory.  
      This chemical and stereochemical efficiency of this approach was first successfully tested in 
the synthesis of (-)-Monomorine since this is a compound that has been enantioselectively 
synthesized and well chracterized.13 The aldehyde 25 was selected as the building block due to 
its desired flexibility for a good chiral building block. It has the orthogonal reactivity of the 
aldehyde, ester and the N-Cbz protecting group as well as the asymmetry of cis-2,5-appendages 
which can all be developed into a diversity of functional groups.  
 
 
Scheme 2.7 Synthesis of pyrrolidine building block 
Reagents and conditions: a) 37% HCl, reflux, 24 h; b) 1. (PhO)2P(O)N3, DMAP, Na2CO3, 
CH2Cl2, rt, 48 h; 2. 1 N HCl, reflux, 1 h; c) Cbz-Cl, K2CO3, toluene, reflux, 48 h; d) HC(OCH3)3, 
PTSA•H2O; e) 1. O3, CH2Cl2, – 78 °C; 2. Ph3P, rt.  
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      Confiscated grade (-)-cocaine was used as the starting material in sufficient quantities to 
provide the chiral building block for the syntheses. Although it is not commercially available, 
confiscated (-)-cocaine can be obtained from the National Institute on Drug Abuse with 
appropriate DEA licensing. As illustrated in Scheme 2.7, (-)-cocaine hydrochloride was treated 
with concentrated hydrochloric acid and reflux. Hydrolysis and condensation provided (-)-
anhydroecgonine hydrochloride 22 in a quantitative yield. A suspension of the carboxylic acid 22 
in dichloromethane was treated with diphenylphosphoryl azide (DPPA) and a catalytic amount of 
DMAP. The reaction took 48 hours at room temperature and it afforded the corresponding acyl 
azide. Without purification, the residue of acyl azide was taken up in hydrochloric acid and 
refluxed. This step converted the acyl azide to the desired (+)-2-tropinone 23 via a Curtius 
rearrangement.   
      The 2-tropinone 23 was demethylated and simultaneously the nitrogen was protected as the 
Cbz-carbamate. This reaction was done by heating the mixture of Cbz-Cl and K2CO3 in toluene 
to 120 ⁰C for 48 hours when the progress of the reaction stopped indicated by TLC. This step 
reduced the basicity associated with the nitrogen atom and protected it from oxidation during the 
ozonolysis step. The N-Cbz-2-tropinone 2 was then treated with trimethyl orthoformate in the 
presence of PTSA•H2O as catalyst. This step converted N-Cbz-2-tropanone into the methyl enol 
24 which was unstable on silica gel and had a very short shelf life. Without further purification, 
the methyl enol ether was brought to ozonolysis. At -78 ⁰C, ozone was bubbled through the 
solution of methyl enol ether in dichloromethane till the solution turned light blue and the blue 
color persisted which indicated the complete cleavage of the double bond. The addition of 
triphenylphosphine subsequently reduced the intermediate to the enantiopure tricarbonyl 
derivative 25.    
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Scheme 2.8 Synthesis of (-)-Monomorine 
Reagents and conditions: a) CH(OCH3)3, CeCl3•7H2O; b) 1. DIBAL-H, toluene, -78 ⁰C; 2. 
Ph3PCH2CCH2CH3Br, t-BuOK, toluene; 3. PTSA.H2O, Acetone; c) (CH3O)2POCH2COCH3, 
LiCl, DBU, CH3CN; d) H2 (55 psi), 10% Pd/C, CH3OH. 
 
      In the synthesis of (-)-monomorine 3 (Scheme 2.8), the right butyl side chain was initially 
built from the ester moiety. This approach avoided the protection and deprotection of this ester 
functional group at a later stage. Thus, the aldehyde moiety was protected as the acetal 26 (in a 
92% yield) with trimethyl orthoformate catalyzed by cerric chloride. When the solution of 
DIBAL-H in THF was added slowly at a low temperature of -78⁰C, the ester group was cleanly 
reduced to aldehyde 27 which was directly introduced to the Wittig olefination reaction adding a 
four-carbon unit for the side-chain. Hydrogenation of the olefin at this point was not necessary 
since it could be done concomitantly with the ring closure step at the last step. The acetal group 
was subjected to hydrolysis when it was treated with PTSA•H2O at room temperature affording 
the aldehyde 27 in a 55% overall yield for three steps. Olefination of 27 with 
trimethylphosphonoacetate, lithiumchloride, and DBU gave the diene 28 in a form of the mixture 
of two isomers in an 80% yield. The construction of the indolizidine ring system was the key 
step for the synthesis of (-)-monomorine. It was completed with a simultaneous 
hydrogenation/reductive animation of 28.  The hydrogenation of the side olefin moieties, 
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deprotection of the pyrrolidine nitrogen, and reductive animation/ring closure all ran smoothly 
with the application of hydrogen (55 psi) over 10% Pd/carbon. During the sequence of the 
reactions, Z/E olefinations isomers were not separated since the later hydrogenation step would 
lead all to the same compound. The relative stereochemistry and absolute configuration of the 
synthesized (-)-monomorine product was confirmed by a good match of our collected analytical 
data of compound 29 with the published analytical data for (+)-monomorine in literature.   
 
Synthesis of (+)-cis-pyrrolidine 225H 
 
Scheme 2.9 Revised synthetic route of building block 
Reagents and conditions: a) EtOOCCl, K2CO3, toluene, reflux, 12 h; b) 37% HCl, reflux, 10 h; c) 
1. (PhO)2P(O)N3, DMAP, Na2CO3, CH2Cl2, rt, 24 h; 2. 1 N HCl, reflux, 1 h; 3. Cbz-Cl, CH2Cl2; 
d) 1. KH, THF, 0 ⁰C, 1 h; 2. TBDMS-Cl, rt, overnight; e) 1. O3, MeOH/CH2Cl2, – 78 °C; 2. 
NaBH4, 0 °C; 3. CH2N2, Et2O, 0 °C, 30 min. 
 
      We were pleased to see the chemical and stereochemical efficiency of our new synthetic 
strategy in the preparation of (-)-monomorine. To further apply this methodology to synthesize 
other amphibian alkaloids and the general synthesis of natural products and drug candidates, we 
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felt the need to optimize our reaction sequences to prepare the building block more rapidly and 
more efficiently.  
      Building block 25 (Scheme 2.8) was synthesized in a moderate yield of 31% over five steps 
and it took a long cycle to prepare 25 from our starting material natural product (-)-cocaine with 
24 hours and 48 hours reaction time for the first step and the second step respectively. The 
demethylation/protection step provided the product in a moderate yield (56%). The overall yield 
was also limited by the ozonolysis step where the low yield was believed to have caused by 
impurities brought from the previous step.  
      Targeting at the resolution of these problems, we designed a different synthetic route to make 
the building block 25. In our previous synthesis, we noticed that the overall yield of the (+)-2-
tropinone 23 varied with the quality of the confiscated (-)-cocaine. To minimize this influence, 
we simply purified the (-)-cocaine by extraction. The confiscated (-)-cocaine hydrochloride salt 
was first dissolved in water and the aqueous solution was washed by ethyl ether to removed trace 
of organic impurities. The aqueous solution was then basified to pH =10 with saturated sodium 
carbonate aqueous solution and extracted by dichloromethane. This procedure eliminated 
potential water-soluble inorganic impurities. We realized that the difficulty of the Cbz-protection 
on the nitrogen could be caused by the β-carbonyl group on 23. The β-carbonyl group made the 
nitrogen more hindered and the lone pair electrons on nitrogen less reactive with the 
chloroformate reagent. But if the demethylation/deprotection step was done before the β-
carbonyl was introduced, the difficulty of reaction could then be avoided. In the revised building 
block synthetic route (Scheme 2.10), demethylation was done as the first step accompanied by 
protection with ethyl chloroformate. This provided 30 in almost a quantitative yield and 
chromatography purification provided a clean intermediate for the next two steps. The carbamate 
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30 was refluxed in concentrated hydrochloric acid for 12 hours. Hydrolysis of two ester groups, 
one amide, and dehydrogenation all proceeded concomitantly giving the α,β-unsaturated 
carboxylic acid 31. The acid 31 reacted with diphenylphosphoryl azide catalyzed by DMAP in 
dichloromethane giving the intermediate acyl azide which then underwent Curtius rearrangement 
releasing nitrogen gas and carbon dioxide gas upon decomposition.14 It was not easy and not 
necessary to separate the intermediate (1R,5S)-8-azabicyclo[3.2.1]octan-2-one from DMAP since 
they share similar chemical and physical properties. The crude mixture reacted with benzyl 
chloroformate to protect the nitrogen and reduce its basicity. Since this was a heterogenous 
reaction, the yield of this one-pot three-step reaction was closely related to the dryness of the 
reactant carboxylic 31. Completely drying and finely grinding the acid 30 was found to greatly 
facilitate conversion of the carboxylic acid 31 into acyl azide and as a result could favor the yield 
for those steps giving ketone 2.    
Ketone 2 was treated with NaH followed by the addition of t-buytldimethylsilyl chloride 
to furnish silyl enol ether 32 according to the procedure reported by Rassat and coworkers.15 
Compared with methyl enol ether, silyl enol ether was more stable to acid conditions. Ether 32 
could be purified by silica gel chromatography. The clean product resulted in a significantly 
increased yield for the ozonolysis step. Ozone was freshly generated in our laboratory from 
oxygen. Ozone was slowly and steadily bubbled through the solution of enol ether 32 in the 
mixture of dichloromethane and methanol at a low temperature of -78 ⁰C. When all the enol 
ether was converted and no more ozone was consumed, the solution turned light blue and the 
blue color persisted. The ozonide was formed as the oxidation product but it could only exist in 
solvent at low temperature. Different reducing agents could result in different reduction products 
of the ozonide. When sodium borohydride was used, the two functional groups introduced were 
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carboxylic acid and alcohol. This product was not purified since it was highly polar. Therefore, 
the crude product residue was directly treated with diazomethane to convert the carboxylic acid 
to methyl ester. The new pyrrolidine building block 3 was furnished with 67% yield over three 
steps.4,14  
Diazomethane is a highly explosive material. Diazomethane frequently employed in 
routine work is generally prepared from precursors by dangerous and time-consuming distillation 
and collection. The diazomethane used in the reaction was freshly prepared by simply reacting 
toluenesulphonylmethylnitrosamide (Diazald) with sodium hydroxide in methanol in a simplified 
apparatus designed for this reaction. The stream of diazomethane was bubbled through the 
solution of intermediate carboxylic acid in ethyl ether and the reaction was done in minutes to 
afford 3 in a good yield. This revised synthetic route gave the new building block 3 in a 51% 
yield from (-)-cocaine.   
 
 
Scheme 2.10 Synthesis of (+)-Pyrrolidine 225H 
Reagents and conditions: a) 1. Oxalyl chloride, DMSO, Et3N, -78 ºC; b) 
(Ph3PCH2CH2CH2CH3)Br, KH, THF, rt; c) DIBAL-H, CH2Cl2, -78 ºC; d) 
(Ph3PCH2CH2CH2CH3)Br, KH, THF, rt; e) H2, Pd/C, MeOH, rt, overnight. 
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      In the synthesis of pyrrolidine 225H, no protection of either the alcohol functional group or 
the ester moiety was necessary when the reactions were under taken in the right sequence. The 
alcohol 3 was oxidized to aldehyde 25 following the Swern oxidation. The aldehyde 25 coupled 
with triphenylphosphoniumbutyl bromide gave a mixture of Z/E olefin with the ration of 5:1. 
The Z isomer was isolated and reduced by DIBAL-H. Although alcohol usually appeared as 
over-reduction product, the reaction ran cleanly to give aldehyde as the exclusively only 
reduction product with a very small amount starting material remained, when the DIBAL-H 
solution was added dropwise at a strictly controlled low temperature. Wittig reaction of the 
aldehyde 34 coupled again with triphenylphosphoniumbutyl bromide furnishing 35. This step 
produced four products, likely the isomers of Z-cis-pyrrolidine, E-cis-pyrrolidine, Z-trans-
pyrrolidine and E-trans-pyrrolidine as the result of epimerization associated with the Wittig basic 
reaction conditions. Fortunately, all those four isomers were easily separated on silica gel 
column chromatography. At that point we assume that the predominantly major product was Z-
cis-pyrrolidine isomer and it was exposed to hydrogen (1 atm) with 10% Pd/carbon. 
Hydrogenation of the two double bonds and the removal of Cbz protection group went 
simultaneously giving (+)-pyrrolidine 225H.  
            The absolute configuration of cis-pyrrolidine 225H has yet to be established and there is 
no reported spectroscopic data or optical rotation data of this compound that we could compare 
with our product. With the asymmetry of the appendages, the intermediates existed as a complex 
mixture of two conformers (rotomers) due to hindered rotation of the N-Cbz bond. The existence 
of rotomers significantly complicated the NMR spectroscopy of late stage intermediates and 
made it difficult to fully and accurately characterize intermediate compounds spectroscopically. 
As a result, we decided to synthesize the other enantiomer of cis-pyrrolidine 225H and to 
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compare the optical rotation data collected from both of the synthetic enantiomers. If our 
synthetic route especially the last hydrogenation step did not cause eperimerization of any 
asymmetric center, the optical rotation of the two enantiomers should be opposite to each other. 
The synthesis was completed following steps in described in Scheme 2.12 affording (-)-cis-
pyrrolidine 225 39. The spectroscopic data of 39 (NMR) was identical with that of 5. The optical 
rotation of 39 ([α]D25 -19.6 (c 0.5, CH3OH)) was determined to be nearly opposite to that of 5 
([α]D25 +21.9 (c 1.0, CH3OH)). This supported that both of the enantiomers of cis-pyrrolidine 
225H have been synthesized in our laboratory from the building block in a stereocontrolled 
manner.  
 
 
Scheme 2.11 Synthesis of (-)-Pyrrolidine 225H 
Reagents and conditions: a) 1. Oxalyl chloride, DMSO, Et3N, -78 ºC; b) (Ph3PCH2CH2CH3)Br,  
KH, THF, rt; c) 1. DIBAL-H, CH2Cl2, -78 ºC; 2. (Ph3PCH2CH2CH2CH2CH3)Br, KH, THF, rt; c) 
H2, Pd/C, MeOH, rt, overnight. 
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Formal Synthesis of (+)-Gephyrotoxin 
 
 
Scheme 2.12 Synthesis of Kishi’s Intermediate 
Reagents and conditions: a) 1. TBDPS-Cl, imidazole, DMF; b) DIBAL-H, toluene, -78 ºC; c) 1. 
(Ph3PCH2OCH3)Cl, t-BuOK, THF; 2. PTSA•H2O, acetone; d) 1. NaBH4, MeOH; e) 1. TsCl, 
pyridine, rt; 2. 1,3-Cyclohexanedione, t-BuOK, THF, 0 ºC; f) H2 (1 atm), Pd/C, MeOH, rt, 
overnight; g) TBAF, DMF. 
 
      As demonstrated in Scheme 2.13, Kishi’s intermediate has two asymmetric centers which 
can be directly introduced from our building block 3. With the cis-2,5-disubstituted pyrrolidine 3 
in hand, our attention was directed toward the construction of the remaining rings of tricyclic 
ketone 9.   To this end, a one-carbon homologation sequence was used to install the C5 atom of 
the tricyclic system 9.  The alcohol 3 was initially converted into silyl ether 40 using TBDPS-Cl 
in a 93% yield.16 The ester unit of 40 was then reduced using DIBAL-H to furnish the 
corresponding aldehyde 41 in an 83% yield. Wittig olefination of 41 using a preformed ylide 
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generated from Ph3PCH2OCH3Cl and t-BuOK gave the methyl enol ether. Subsequent hydrolysis 
of the enol moiety with PTSA·H2O in acetone furnished the desired aldehyde 42 in a 79% yield 
over the two-step sequence. Although we only observed one compound with the right NMR 
spectrum, there was the potential for epimerization at C5 of 41. We continued on with the 
intention of characterizing any diastereoisomers at a later stage in the synthesis.   
      Aldehyde 42 was reduced carefully with DIBAL-H. The product alcohol 43 was converted to 
its tosylate and then coupled with 1,3-cyclohexanedione .16 This one-step coupling method 
afforded the dione 44 in a 93 % yield.  Subsequent hydrogenation of the dione 44 catalyzed by 
10% Pd/C furnished the tricyclic amine as a mixture of diastereoisomers (9:1) in 75% yield via 
sequential Cbz removal, cyclization and enolamine elimination. Two isomers were observed as 
products with very similar NMR spectrum. 
      The rigid nature of the tricyclic ring system facilitated the structural characterization of the 
diastereoisomers. The two diastereoisomers were readily distinguished by 13C and 1H NMR but 
were not easily separated by column chromatography. Presumably the minor isomer resulted 
from epimerization of C5 during the ozonolysis, the DIBAL-H reduction or the Wittig 
olefination steps. Nevertheless, the minor diastereoisomer could be readily removed after the 
subsequent step. Removal of the silyl-protecting group with TBAF gave a separable mixture of 
diastereoisomers and furnished Kishi’s intermediate 9 in an 87% yield in its enantiopure form. 
The NMR spectra were consistent with previously reported data9-12 and the absolute 
configuration of 9 was unequivocally established by X-ray crystallography. 
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2.4 CONCLUSIONS 
 
      Our efficient and expeditious approach exploits the inherent stereochemistry of a (1R)-2-
tropinone derivative 2 prepared from (-)-cocaine 1 for the construction of the core cis-2,5-
disubstuted pyrrolidine ring system. Utilizing this intermediate as a building block, the 
enantioselective syntheses of both of the (+)-cis-pyrrolidine 225H in a 31% yield and (-)-cis-
pyrrolidine 225H in a 29% yield were achieved. An enantioselective synthesis of the tricyclic 
gephyrotoxin skeleton was also successfully conducted. The synthesis provided Kishi’s 
intermediate in an enantiopure form in a 19% overall yield and constitutes a formal synthesis of 
(+)-gephyrotoxin 287C.    
 
2.5 EXPERIMENTAL SECTION  
General Experimental Methods 
      All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. Anhydrous dichloromethane was purchased from Mallinckrodt Baker, Inc. 
Confiscated grade (-)-cocaine hydrochloride was provided by NIDA Drug Supply System, 
Research Technology Branch, National Institute on Drug Abuse. Proton and carbon NMR were 
recorded on a Varian-400 MHz nuclear magnetic resonance spectrometer at ambient temperature 
in CDCl3 from Cambridge Isotope Laboratories, Inc. 1H NMR chemical shifts are reported as δ 
values (ppm) relative to tetramethylsilane. 13C NMR chemical shifts are reported as δ  values 
(ppm) relative to chloroform-d (77.0 ppm). Optical rotations were measured on Autopol III 
polarimeter at the sodium D line (2 mL sample cell). Melting points (mp) were measured with an 
Electrothermal R Mel-Temp apparatus and are uncorrected.  
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      (1R,2R,3S,5S)-8-Ethyl 2-methyl 3-(benzoyloxy)-8-azabicyclo[3.2.1]octane-2,8-
dicarboxylate (30) Confiscated (-)-cocaine hydrochloride salt (20 g) was dissolved in water (50 
mL). The aqueous solution was washed by ether to remove the trace of organic impurity. The 
saturated Na2CO3 in water was added till pH=10. The resultant slurry of white solid was treated 
with dichloromethane (100 mL). The aqueous portion was discarded. The organic solution was 
dried on anhydrous Na2SO4, filtered, and concentrated in vacuo giving the pure (-)-cocaine (18.1 
g, 100%) 
      Pure (-)-Cocaine (9.76 g, 32.1 mmol) and NaHCO3 (4.05 g, 48.3 mmol) were taken up in 100 
mL of anhydrous toluene. To the suspension was added ethyl chloroformate (17.45 g, 15.30 mL, 
160.8 mmol). The reaction mixture was heated to reflux at 120 °C. After 12 hours, another 
portion of ethyl chloroformate (10.47 g, 9.18 mL, 96.5 mmol) was added. The stirring and 
refluxing continued for additional 12 hours till the TLC indicated the complete conversion of the 
starting material. Toluene was removed under reduced pressure. The residue was portioned 
between EtOAc (100 mL) and water (100 mL). The aqueous layer was separated and the aqueous 
layer was extracted with EtOAc (2 x 100 mL). Combined organic portions were washed by 
saturated Na2CO3 in water (100 mL), brine (100 mL), dried on anhydrous MgSO4, filtered, and 
concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
EtOAc/hexanes = 1:2) affording 30 (11.37 g, 31.46 mmol, 98%) as a slightly yellow oil.  Rf = 
0.34 (EtOAc/hexanes = 1:2). [α]D25 -30.4 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.98-
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7.90 (m, 2H), 7.59-7.51 (m, 1H), 7.42-7.37 (m, 2H), 5.50-5.41 (m, 1H), 4.76-4.41 (m, 2H), 4.20-
4.00 (m, 2H), 3.63 (s, 3H), 3.09 (brs, 1H), 2.61-2.56 (m, 1H), 2.18-1.72 (m, 5H), 1.30-1.19 (m, 
3H). 13C NMR (CDCl3)  δ170.4, 166.0, 153.9, 133.3, 129.7, 128.5, 66.7, 61.23, 61.12, 54.89, 
54.60, 52.55, 52.37, 51.95, 51.63, 49.38, 48.92, 33.67, 33.28, 28.91, 28.20, 27.94, 27.32, 14.75. 
Anal. Calcd. for C19H23NO6: C, 63.15; H, 6.41; N, 3.88. Found: C, 63.22; H, 6.49; N, 3.91.  
 
 
      (1R,5S)-8-Azabicyclo[3.2.1]oct-2-ene-2-carboxylic acid hydrochloride (31) 30 (10.14 g, 
28.5 mmol) was taken up in 100 mL of concentrated hydrochloric acid (12 N). The reaction was 
heated to reflux at 120 °C for 6 hours. After being cooled to room temperature, the aqueous 
solution was washed by ether (2 x 50 mL). Most of the water was removed under high vacuum at 
elevated temperature. Then the slurry was azeotropic distilled with toluene twice to remove the 
remaining water. The resultant solid was dried in a oven under vacuum (30 torr, 80 °C) for 12 
hours. The solid was ground into fine powder and heated again in the oven for 12 hours giving 
the desired product 31 (5.41 g, 28.5 mmol) as a white powder. Mp/Dec. 260-262⁰C. Anal. Calcd 
for C8H12ClNO2: C, 50.67; H, 6.38; N, 7.39. Found: C, 50.38; H, 6.39; N, 7.27. 
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      (1R,5S)-Benzyl 2-oxo-8-azabicyclo[3.2.1]octane-8-carboxylate (2) The finely powdered 31 
(3.216 g, 17.0 mmol) and sodium carbonate (4.50 g, 42.50 mmol) ware suspended in 100 mL of 
anhydrous dichloromethane followed by the addition of 4-dimethylaminopyridine (104 mg, 0.84 
mmol). The suspension was purged with N2, sealed, and stirred for 15 minutes before 
diphenylphosphoryl azide (5.71 g, 4.48 mL, 20.74 mmol) was added dropwise. The stirring was 
continued for 48 hours. Solvent was removed in vacuo. The mixture slurry was taken up in 40 
mL of water. At 0 °C, 120 mL of hydrochloric acid (1 N in water) was added slowly and 
carefully with the evolution of gas. The aqueous solution was then heated in a preheated oil bath 
(120 °C) for 40 minutes until the carbon dioxide and nitrogen gas evolution ceased. The aqueous 
hydrochloric acid solution was removed under reduced pressure. The residue was basified (pH 
9.5-10) by the addition of saturated Na2CO3. The aqueous solution was then extracted with 
CH2Cl2 (2 x 50 mL). The combined organic portions were washed by brine (50 mL), dried on 
anhydrous MgSO4, filtered, and concentrated in vacuo. The residue without further purification 
was dissolved in the mixture of 108 mL of MeOH and 12 mL of water. At 0 °C, sodium 
bicarbonate (4.6 g) was added followed by the addition of benzyl chloroformate (2.4 mL). The 
reaction mixture was stirred at room temperature for 5 hours. The solvent methanol was removed 
under reduced pressure. The aqueous solution was diluted with 50 mL of water and extracted 
with CH2Cl2 (2 x 50 mL). Combined organic fractions were washed by brine, dried on anhydrous 
MgSO4, filtered, and concentrated in vacuo. The residue was purified by a flash chromatography 
(SiO2, EtOAc/hexanes = 1:2) affording 2 (3.84 g, 14.79 mmol, 87%) as a clear oil. 1H NMR 
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(400 MHz, CDCl3) δ7.39-7.27 (m, 5H), 5.19-5.07 (m, 2H), 4.54-4.44 (m, 2H), 2.48-2.42 (m, 2H), 
2.38-2.32 (m, 2H), 2.25-2.18 (m, 2H), 1.86-1.77 (m, 2H). 13C NMR (CDCl3)  δ205.5, 154.0, 
136.5, 128.6, 128.2, 128.0, 67.2, 64.3, 53.0, 32.6, 30.6, 28.0, 27.2. Anal. Calcd for C15H17NO3: C, 
69.48; H, 6.61; N, 5.40. Found: C, 69.65; H, 6.65; N, 5.29.  
 
 
      (1R,5S)-benzyl 2-(tert-butyldimethylsilyloxy)-8-azabicyclo[3.2.1]oct-2-ene-8-carboxylate 
(32) Under nitrogen atmosphere, NaH (60 mg, 2.5 mmol) was suspended in anhydrous THF (4 
mL). At 0 °C, a solution of compound 2 (130 mg, 5 mmol) in dry THF (2 mL) was added 
dropwise and stirred for 2 hours. Then TBDMSCl (1.0 M in THF, 1 mL) was added dropwise 
and stirred overnight at room temperature. At 0 °C, the reaction was quenched by a slow addition 
of water (10 mL) and diluted with ethyl ether (20 mL). The organic fraction was separated and 
the aqueous was extracted with ethyl ether (2 x 20 mL). Combined organic portions were dried 
on MgSO4, filtered, and concentrated. The crude product was purified by a flash chromatography 
(SiO2, eluting with EtOAc/Hexanes = 5:95) to afford 32 (166 mg, 89% yield) as a colorless oil.      
[α]D25 -43.5 (c 1.2, CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.28-7.35 (m, 5H), 5.09-5.19 (m, 
2H), 4.11-4.49 (m, 2.5H), 2.61-2.79 (m, 0.5H), 1.94-2.18 (m, 3H), 1.74 (dd, J = 16.4, 4.6, 1H), 
1.58-1.67 (m, 2H), 0.90 (s, 9H), 0.14 (m, 6H). 13C NMR (75 MHz, CDCl3) δ 154.8., 154.4, 137.1, 
128.6, 128.1, 128.0, 97.3, 66.8, 57.7, 52.5, 34.4, 33.7, 32.4, 31.4, 30.2, 29.4, 25.8, 18.2, -4.5, -4.1, 
Anal. Calcd for C21H31NO3Si: C, 67.52; H, 8.36; N, 3.79. Found: C, 67.73; H, 8.58; N, 3.79. 
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      (2R,5S)-1-benzyl 2-methyl 5-(2-hydroxyethyl)pyrrolidine-1,2-dicarboxylate (3)  Silyl 
ether 32 (781 mg, 2.1 mmol, 1.0 equiv) was dissolved in the solution of CH2Cl2 (50 mL) + 
CH3OH (5 mL). At -78 °C, O3 was bubbled into the solution till a light blue color was observed 
and persisted. A stream of N2 was bubbled through for 10 minutes. At -78 °C, NaBH4 (250 mg) 
was added by one portion. After 30 minutes, another portion of NaBH4 (300 mg) was added and 
the reaction was warmed to room temperature. The solvent was removed under reduced pressure. 
The residue was triturated with 2N HCl (25 mL) to pH<1. The aqueous solution was extracted 
with CH2Cl2 (3 × 20 mL). Combined organic portions were dried on anhydrous MgSO4, filtered, 
and concentrated affording a slightly yellow oil.  
      CH2N2 gas was freshly prepared from p-toluenesulphonylmethylnitrosamide (Diazald) and 
bubbled through the solution of the previous oil in Et2O (20 mL) at 0°C. When a yellow color 
was observed in the solution, CH2N2 stream was removed and N2 was bubbled through the 
solution for 5 minutes. The reaction was warmed to room temperature and the solvent was 
removed in vacuo. The residue was purified by a flash chromatography (SiO2, eluting with 
hexanes/EtOAc = 4:6) affording ester 3 (430 mg, 67% yield, 3 steps) as a colorless oil. [α]D25 
+52 (c 0.6, CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.28-7.37 (m, 5H), 5.03-5.22 (m, 2H), 4.37 
(t, J = 8.3, 1H), 3.93 (dd, J = 9.8, 4.6, 1H), 3.64-3.82 (m, 3H), 3.60 (s, 3H), 2.30-2.37 (m, 1H), 
1.95-2.11 (m, 2H), 1.61-1.82 (m, 3H). 13C NMR (75 MHz, CDCl3) δ 173.6, 156.1, 136.4, 128.7, 
128.3, 127.9, 67.8, 59.9, 59.1, 55.8, 52.4, 37.8, 30.9, 29.2. Anal. Calcd for C16H21NO5: C, 62.53; 
H, 6.89; N, 4.56. Found: C, 62.28; H, 7.00; N, 4.49. 
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      (2R,5S)-1-benzyl 2-methyl 5-(2-oxoethyl)pyrrolidine-1,2-dicarboxylate (25) Under N2, 
oxalyl chloride (150 mg, 0.1 mL, 1.18 mmol) was taken up in 30 mL of CH2Cl2 and cooled to -
78 °C in a dry ice/acetone bath. Dimethyl sulfoxide (184 mg, 0.17 mL, 2.25 mmol) was added 
dropwise. The mixture was stirred at -78 °C for 10 minutes before a solution of the alcohol 3 
(300 mg, 1.07 mmol) in 2 mL CH2Cl2 was added slowly. The mixture again was stirred for 15 
minutes. Then triethyl amine (541 mg, 0.75 mL, 5.35 mmol) was added and the reaction was 
warmed to room temperature. Water (30 ml) was added. The organic layer was separated and the 
aqueous layer was extracted with CH2Cl2 (2 x 30 mL). Combined organic portions were washed 
by brine, dried on anhydrous MgSO4, filtered, and concentrated. The residue was purified by a 
silica gel column eluting with 1:1 EtOAc/hexanes affording the product (294 mg, 90%) as a clear 
oil. [α]D25 +23.6 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 9.81 (s, 0.6H), 9.71 (s, 0.4H), 
7.35-7.27 (m, 5H), 5.19-5.03 (m, 2H), 4.50-4.32 (m, 2H), 3.74 (s, 1.2H), 3.61 (s, 1.8H), 3.24 (dd, 
J = 20, 3.7, 0.6H), 3.05 (dd, J = 20, 3.7, 0.4H), 2.72-2.62 (m, 1H), 2.27-2.16 (m, 2H), 2.03-1.94 
(m, 1H), 1.75-1.66 (m, 1H). 13C NMR (CDCl3) δ 200.9, 200.7, 173.2, 173.0, 154.3, 153.9, 136.3, 
136.1, 128.5, 128.4, 128.2, 128.1, 128.0, 127.6, 67.3, 67.0, 59.9, 59.5, 54.0, 53.2, 52.3, 52.1, 48.9, 
48.2, 31.0, 30.2, 28.9, 28.0, 22.2. Anal. Calcd for C16H19NO5: C, 62.94; H, 6.27; N, 4.59. Found: 
C, 62.51; H, 6.53; N, 4.49. 
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      (2R,5S)-1-benzyl 2-methyl 5-((Z)-hex-2-enyl)pyrrolidine-1,2-dicarboxylate (33) 
Potassium hydride (40% in mineral oil) was washed by anhydrous hexanes and dried by a stream 
of argon. Potassium hydride (47.3 mg, 1.18 mmol) and Ph3P(CH2)3CH3Br (628 mg, 1.572 mmol) 
were suspended in 10 mL of anhydrous THF. The reaction was stirred under the atmosphere of 
N2 at room temperature for 30 minutes and then cooled to 0 °C in an ice water cold bath. At 0 °C, 
the solution of aldehyde 25 (120 mg, 0.393 mmol) in 1 mL of THF was added dropwise. Upon 
the completion of addition, the cold bath was removed and the reaction mixture was stirred at 
room temperature for one hour. The reaction was quenched by the addition of 1 mL of saturated 
ammonium chloride aqueous solution. The reaction was then partitioned between EtOAc (20 mL) 
and water (20 mL). The top organic layer was separated. The aqueous layer was extracted with 
EtOAc (2 x 20 mL). Combined organics were washed by brine, dried on anhydrous MgSO4, 
filtered, and concentrated under reduced pressure. The residue was purified by a silica gel 
column chromatography eluting with 1:4 EtOAc/hexanes affording the Z-alkene (85 mg, 85%) 
as the predominant major isomer. Rf = 0.44 (EtOAc:Hexanes = 1:4). [α]D25 +15.6 (c 1.0, 
CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.39-7.22 (m, 5H), 5.53-5.44 (m, 2H), 5.43-5.29 (m, 
2H), 4.41-4.30 (m, 1H), 4.00-3.83 (m, 1H), 3.77 (s, 1.4H), 3.61 (s, 1.6H), 2.84-2.62 (m, 1H), 
2.31-2.13 (m, 2H), 2.10-1.87 (m, 4H), 1.84-1.70 (m, 1H), 1.42-1.34 (m, 2H), 0.93 (t, J = 0.68, 
1.6H), 0.84 (t, J = 0.68, 1.4H). 13C NMR (CDCl3) δ 173.5, 173.3, 154.9, 154.1, 136.6, 136.5, 
132.4, 132.2, 128.4, 128.3, 128.0, 127.8, 127.6, 125.6, 125.3, 67.2, 66.8, 60.2, 59.8, 59.2, 58.6, 
103 
 
52.1, 52.0, 32.0, 31.2, 29.4, 29.3, 29.0, 28.7, 28.0, 22.7, 22.6, 13.7, 13.6. Anal. Calcd for 
C20H27NO4: C, 69.54; H, 7.88; N, 4.05. Found: C, 69.34; H, 8.01; N, 4.21. 
 
 
      (2R,5S)-benzyl 2-formyl-5-((Z)-hex-2-enyl)pyrrolidine-1-carboxylate (34) Methyl ester 
33 (100 mg, 0.289 mmol) was taken up in 15 mL of anhydrous CH2Cl2 and cooled to -78 °C in a 
dry ice/acetone bath. At -78°C, diisobutylaluminium hydride (DIBAL-H, 1 M in toluene, 0.376 
mL) was added dropwise in a period of 30 minutes. After the completion of addition, the reaction 
mixture was stirred at -78 °C for two hours till the starting material disappeared monitored by 
TLC. The reaction was quenched by the addition of 0.5 mL of MeOH and warmed up to room 
temperature. The mixture was poured into ice-cold hydrochloric acid solution in water (1 N). The 
aqueous layer was extracted with CH2Cl2 (2 x 20 mL). Combined organic portions were washed 
by brine, dried on anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The 
residue was purified by a silica gel column chromatography eluting with 1:4 EtOAc/Hexanes 
affording the aldehyde (86 mg, 95%). [α]D25 +4.6 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 
9.83 (s, 0.5H), 9.74 (s, 0.5H), 7.39-7.22 (m, 5H), 5.53-5.44 (m, 2H), 5.43-5.29 (m, 2H), 4.45-
4.39 (m, 1H), 4.00-3.83 (m, 1H), 2.84-2.62 (m, 1H), 2.31-2.13 (m, 2H), 2.08-1.78 (m, 4H), 1.84-
1.70 (m, 1H), 1.42-1.34 (m, 2H), 0.93 (t, J = 0.68, 1.6H), 0.84 (t, J = 0.68, 1.4H). 13C NMR 
(CDCl3) δ 200.6, 156.0, 154.8, 136.4, 133.1, 128.9, , 128.0, 127.2, 67.9, 67.7, 66.3, 66.1, 59.9, 
58.7, 32.5, 31.9, 29.8, 28.3, 26.0, 24.8, 22.9. Anal. Calcd for C19H25NO3: C, 72.35; H, 7.99; N, 
4.44. Found: C, 72.09; H, 8.07; N, 4.19. 
104 
 
 
      (2S,5R)-benzyl 2-((Z)-hex-2-enyl)-5-((Z)-pent-1-enyl)pyrrolidine-1-carboxylate (35)  
Potassium hydride (40% in mineral oil) was washed by anhydrous hexanes and dried by a stream 
of argon. Potassium hydride (50 mg, 1.25 mmol) and Ph3P(CH2)3CH3Br (663 mg, 1.66 mmol) 
were suspended in 10 mL of anhydrous THF. The reaction was stirred under the atmosphere of 
N2 at room temperature for 30 minutes and then cooled to 0 °C in an ice/water cold bath. At 0 °C, 
the solution of aldehyde (131 mg, 0.415 mmol) in 1 mL of THF was added dropwise. Upon the 
completion of addition, the cold bath was removed and the reaction mixture was stirred at room 
temperature for one hour. The reaction was quenched by the addition of 1 mL of saturated 
ammonium chloride aqueous solution. The reaction was then partitioned between EtOAc (20 mL) 
and water (20 mL). The organic layer was separated. The aqueous layer was extracted with 
EtOAc (2 x 20 mL). Combined organic fractions were washed by brine, dried on anhydrous 
MgSO4, filtered, and concentrated under reduced pressure. The residue was purified by a silica 
gel column chromatography eluting with 1:11 EtOAc/hexanes affording the Z-alkene (116 mg, 
0.328 mmol, 85%) as the predominant major isomer. [α]D25 -117.7 (c 1.5, CH3OH). 1H NMR 
(400 MHz, CDCl3) δ 7.40-7.23 (m, 5H), 5.55-5.30 (m, 4H), 5.12 (s, 2H), 4.61-4.57 (m, 1H),  
3.95-3.85 (m, 1H), 2.62-2.51 (m, 2H), 2.20-1.80 (m, 6H), 1.80-1.60 (m, 4H), 1.51-1.18 (m, 4H), 
1.00-0.85 (m, 4H) 13C NMR (CDCl3) δ 155.5, 137.1, 133.2, 130.5, 130.1, 128.4, 128.1, 128.0, 
125.9, 67.7, 59.0, 56.2, 32.9, 31.7, 30.0, 22.8, 14.3. Anal. Calcd for C23H33NO2: C, 77.70; H, 
9.36; N, 3.94. Found: C, 77.66; H, 9.49; N, 4.08. 
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      (+)-cis-Pyrrolidine 225H (5) Diene 35 (45 mg, 0.126 mmol) was taken up in 10 mL of 
MeOH and 10 mg of 10% Palladium on activated carbon was added. The reaction vessel was 
vacuumed and backfilled with hydrogen. This procedure was repeated three times and a balloon 
filled with H2 was connected to the reaction vessel. The solution was stirred overnight. The 
reaction solution was filtered through a thin pad of celite and washed with 20 mL of EtOAc and 
concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
MeOH/CH2Cl2 = 1:10) affording (+)-cis-pyrrolidine 225H (31.8 mg, 0.124 mmol, 99%) as a 
slightly yellow oil. [α]D25 +21.9 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 2.98-2.88 (m, 
2H), 1.87-1.79 (m, 2H) 1.54-1.21 (m, 22H), 0.92-0.84 (m, 5H). 13C NMR (CDCl3) δ 59.6, 36.98, 
36.94, 32.27, 32.04, 31.54, 29.72, 27.69, 27.42, 22.83, 22.82, 14.29, 14.25. Anal. Calcd for 
C15H31N: C, 79.92; H, 13.86; N, 6.21. Found: C, 79.68; H, 13.97; N, 6.18. 
 
 
      (2R,5S)-1-Benzyl 2-methyl 5-((Z)-pent-2-enyl)pyrrolidine-1,2-dicarboxylate (36) 
Potassium hydride (40% in mineral oil) was washed by anhydrous hexanes and dried by a stream 
of argon. Potassium hydride (60.1 mg, 1.50 mmol) and Ph3P(CH2)2CH3Br (770 mg, 2.0 mmol) 
were suspended in 10 mL of anhydrous THF. The reaction was stirred under the atmosphere of 
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N2 at room temperature for 30 minutes and then cooled to 0 °C in an ice water cold bath. At 0 °C, 
the solution of aldehyde (152.7 mg, 0.50 mmol) in 1 mL of THF was added dropwise. Upon the 
completion of addition, the cold bath was removed and the reaction mixture was stirred at room 
temperature for one hour. The reaction was quenched by the addition of 1 mL of saturated 
ammonium chloride aqueous solution. The reaction was then partitioned between EtOAc (20 mL) 
and water (20 mL). The top organic layer was separated. The aqueous layer was extracted with 
EtOAc(2 x 20 mL). Combined organics were washed by brine, dried on anhydrous MgSO4, 
filtered, and concentrated under reduced pressure. The residue was purified by a silica gel 
column chromatography eluting with 1:4 EtOAc/hexanes affording the Z-alkene (146 mg, 0.44 
mmol, 87%) as the predominant major isomer. Rf = 0.4 (EtOAc:Hexanes = 1:4). [α]D25 +13.0 (c 
1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.39-7.22 (m, 5H), 5.55-5.44 (m, 2H), 5.33-5.27 (m, 
2H), 4.41-4.30 (m, 1H), 4.00-3.83 (m, 1H), 3.77 (s, 1.4H), 3.61 (s, 1.6H), 2.84-2.62 (m, 1H), 
2.31-2.13 (m, 2H), 2.13-1.87 (m, 4H), 1.78-1.70 (m, 1H), 2.32-2.14 (m, 2H), 1.23 (t, J = 0.62, 
1.6H), 1.19 (t, J = 0.62, 1.4H). 13C NMR (CDCl3) δ 173.5, 173.3, 154.9, 154.1, 136.6, 136.5, 
132.4, 132.2, 128.4, 128.3, 128.0, 127.8, 127.6, 125.6, 125.3, 67.2, 66.8, 60.2, 59.8, 59.2, 58.6, 
52.1, 52.0, 32.0, 31.2, 29.4, 28.7, 28.0, 20.7, 20.6, 13.9, 13.7. Anal. Calcd for C19H25NO4: C, 
68.86; H, 7.60; N, 4.23. Found: C, 69.04; H, 7.44; N, 4.21. 
 
 
      (2R,5S)-Benzyl 2-formyl-5-((Z)-pent-2-enyl)pyrrolidine-1-carboxylate (37) Ester 36 (76 
mg, 0.23 mmol) was taken up in 15 mL of anhydrous CH2Cl2 and cooled to -78°C in a dry 
ice/acetone bath. At -78 °C, diisobutylaluminium hydride (DIBAL-H, 1 M in toluene, 0.276 mL) 
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was added dropwise in 30 minutes. After the completion of addition, the reaction mixture was 
stirred at -78 °C for two hours till the starting material disappeared monitored by TLC. The 
reaction was quenched by the addition of 0.5 mL of MeOH and warmed up to room temperature. 
The mixture was poured into ice-cold hydrochloric acid solution in water (1 N). The aqueous 
layer was extracted with CH2Cl2 (2 x 20 mL). Combined organic portions were washed by brine, 
dried on anhydrous Na2SO4, filtered, and concentrated under reduced pressure. The residue was 
purified by a silica gel column chromatography eluting with 1:4 EtOAc/Hexanes affording the 
aldehyde (62.3 mg, 0.207 mmol, 90%). [α]D25 +9.8 (c 1.0, CH3OH). 1H NMR (400 MHz, CDCl3) 
1H NMR (400 MHz, CDCl3) δ 7.39-7.22 (m, 5H), 5.55-5.44 (m, 2H), 5.33-5.27 (m, 2H), 4.41-
4.30 (m, 1H), 4.00-3.83 (m, 1H), 2.84-2.62 (m, 1H), 2.31-2.13 (m, 2H), 2.13-1.87 (m, 4H), 1.78-
1.70 (m, 1H), 2.32-2.14 (m, 2H), 1.23 (t, J = 0.62, 1.6H), 1.19 (t, J = 0.62, 1.4H). 13C NMR 
(CDCl3) δ 200.6, 156.0, 154.8, 136.4, 133.1, 128.9, , 128.0, 127.2, 67.9, 67.7, 66.3, 66.1, 32.5, 
31.9, 29.8, 28.3, 26.0, 24.8, 22.9. Anal. Calcd for C18H23NO3: C, 71.73; H, 7.69; N, 4.65. Found: 
C, 71.36; H, 7.83; N, 4.69. 
 
Potassium hydride (40% in mineral oil) was washed by anhydrous hexanes and dried by a stream 
of argon. Potassium hydride (28.8 mg, 0.72 mmol) and Ph3P(CH2)4CH3Br (409 mg, 0.96 mmol) 
were suspended in 10 mL of anhydrous THF. The reaction was stirred under the atmosphere of 
N2 at room temperature for 30 minutes and then cooled to 0°C in an ice water cold bath. At 0°C, 
the solution of aldehyde (72.2 mg, 0.24 mmol) in 1 mL of THF was added dropwise. Upon the 
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completion of addition, the cold bath was removed and the reaction mixture was stirred at room 
temperature for one hour. The reaction was quenched by the addition of 1 mL of saturated 
ammonium chloride aqueous solution. The reaction was then partitioned between EtOAc (20 mL) 
and water (20 mL). The top organic layer was separated. The aqueous layer was extracted with 
EtOAc(2 x 20 mL). Combined organics were washed by brine, dried on anhydrous MgSO4, 
filtered, and concentrated under reduced pressure. The residue was purified by a silica gel 
column chromatography eluting with 1:4 EtOAc/hexanes affording the Z-alkene (74.7 mg, 0.21 
mmol, 86%) as the predominant major isomer. Rf = 0.4 (EtOAc:Hexanes = 1:4). [α]D25 +42.6 (c 
1.0, CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.40-7.23 (m, 5H), 5.65-5.40 (m, 4H), 5.17 (s, 1H), 
5.12 (s, 1H), 4.61-4.57 (m, 1H),  3.79-3.85 (m, 1H), 2.62-2.51 (m, 2H), 2.20-1.80 (m, 4H), 1.77-
1.62 (m, 4H), 1.51-1.11 (m, 4H), 1.11-0.83 (m, 6H) 13C NMR (CDCl3) δ 155.5, 137.1, 133.2, 
130.5, 130.1, 128.4, 128.1, 128.0, 125.9, 67.7, 59.0, 56.2, 32.9, 31.7, 30.0, 22.8, 14.3. Anal. 
Calcd for C23H33NO2: C, 77.70; H, 9.36; N, 3.94. Found: C, 77.66; H, 9.49; N, 4.08. 
 
 
      (-)-cis-Pyrrolidine 225H (39) Diene 38 (56.8 mg, 0.08 mmol) was taken up in 10 mL of 
MeOH and 10 mg of 10% Palladium on activated carbon was added. The reaction vessel was 
vacuumed and backfilled with hydrogen. This procedure was repeated three times and a balloon 
filled with H2 was connected to the reaction vessel. The solution was stirred overnight. The 
reaction solution was filtered through a thin pad of celite and washed with 20 mL of EtOAc and 
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concentrated in vacuo. The residue was purified by a flash chromatography (SiO2, 
MeOH/CH2Cl2 = 1:10) affording (17 mg, 0.076 mmol, 95%) as a slightly yellow oil. [α]D25 -19.6 
(c 0.5, CH3OH). 1H NMR (400 MHz, CDCl3) δ 2.96-2.88 (m, 2H), 1.80-1.70 (m, 2H) 1.59-1.21 
(m, 22H), 0.95-0.85 (m, 5H). 13C NMR (CDCl3) δ 58.9, 36.98, 36.94, 32.27, 32.04, 31.54, 29.72, 
27.69, 27.42, 22.83, 22.82, 14.29, 14.25. Anal. Calcd for C15H31N: C, 79.92; H, 13.86; N, 6.21. 
Found: C, 79.84; H, 14.20; N, 6.05. 
 
 
      (2R,5S)-1-Benzyl 2-methyl 5-(2-(tert-butyldiphenylsilyloxy)ethyl)pyrrolidine-1,2-
dicarboxylate (40) Under the atmosphere of nitrogen, alcohol 3 (374 mg, 1.22 mmol) and 
imidazole (166 mg, 2.44 mmol) were taken up in dry DMF (15 mL). At 0 °C, TBDPS-Cl (402 
mg, 1.46 mmol) was added dropwise. The reaction was warmed to room temperature and stirred 
overnight. At 0 °C, the reaction was quenched by water (15 mL) and extracted with Et2O (2 × 30 
mL). The combined organic portions were dried on MgSO4, filtered and concentrated in vacuo. 
The residue was purified by a flash column chromatography (SiO2, eluting with EtOAc/Hexane 
= 15:85) affording silyl ether 40 (617 mg, 93% yield) as a colorless oil. [α]D25 +22.1 (c 0.73, 
CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.63 (t, J = 6.4, 4H), 7.26-7.44 (m, 11H), 5.01-5.20 (m, 
2H), 4.31-4.41 (m, 1H), 4.09-4.16 (m, 1H), 3.65-3.79 (m, 4H), 3.58 (s, 1H), 2.15-2.40 (m, 2H), 
1.61-2.02 (m, 4H), 1.03 (d, J = 11.0, 9H). 13C NMR (101 MHz, CDCl3) δ 173.6, 155.1, 136.9, 
135.8, 134.0, 129.8, 128.7, 128.6, 128.1, 127.9, 67.3, 67.0, 62.1, 61.7, 60.2, 59.9, 57.7, 56.5, 52.4, 
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52.2, 37.2, 36.5, 30.2, 29.9, 29.4, 28.4, 27.0, 19.4. Anal. Calcd for C32H39NO5Si: C, 70.43; H, 
7.20; N, 2.57. Found: C, 70.64; H, 7.23; N, 2.56. 
 
 
      (2S,5R)-benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-formylpyrrolidine-1-
carboxylate (41). Under nitrogen, ester 40 (547 mg, 1 mmol) was dissolved in toluene (6 mL). 
At -78 °C, DIBAL-H (1.0 M in toluene, 1.5 mL) was added dropwise over a period of 45 
minutes. The reaction was stirred at -78 °C for 30 minutes and warmed to -40 °C. The reaction 
mixture was diluted with Et2O (10 mL) and reaction was quenched by the addion of 1 N NH4Cl 
(1 mL). Anhydrous MgSO4 was added till the solution became clear. The solution was filtered 
through a thin pad of celite and concentrated in vacuo. The residue was purified by a flash 
column chromatography (SiO2, eluting with EtOAc/hexanes = 1:4) affording aldehyde 41 (431 
mg, 83%) as a colorless oil. [α]D25 +17.3 (c 0.95, CH3OH). 1H NMR (400 MHz, CDCl3) δ 9.48 (s, 
0.5H), 9.35 (s, 0.5H), 7.67 (s, 4H), 7.26-7.46 (m, 11H), 4.13-4.27 (m, 2H), 4.13-4.27 (m, 2H), 
3.59-3.80 (m, 2H), 1.43-2.45 (m, 6H), 1.06 (d, J = 6.7, 9H). 13C NMR (CDCl3) δ 200.5, 155.9, 
154.7, 136.5, 135.8, 133.9, 129.9, 128.8, 128.3, 128.1, 127.9, 67.6, 67.4, 66.3, 65.9, 61.8, 61.6, 
57.7, 56.5, 37.8, 37.3, 30.1, 29.8, 27.1, 26.0, 24.9, 19.4. Anal. Calcd for C31H37NO4Si: C, 72.20; 
H, 7.23; N, 2.72. Found: C, 71.88; H, 7.37; N, 2.61. 
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      (2S,5R)-benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2-oxoethyl)pyrrolidine-1-
carboxylate (42) Under N2, (Ph3PCH2OCH3)Cl (2.50 g, 7.28 mmol) was suspended in dry THF 
(50 mL) in a round-bottomed flask. At 0 ⁰C,  t-BuOK (1.0 M in THF, 6.84 mmol) was added 
dropwise. The solution was stirred at room temperature for 15 minutes and was added dropwise 
to the solution of aldehyde 41 (1.412 g, 2.74 mmol) in dry THF (10 mL) till an orange color 
persisted. Then reaction mixture was stirred at room temperature for additional 15 minutes 
before it was diluted by EtOAc (30 mL) and quenched by the addition of 1 N NH4Cl (20 mL). 
The organic fraction was separated and the aqueous was extracted with EtOAc (2 x 20 mL). 
Combined organic fractions were washed by saturated NaCl, dried on anhydrous MgSO4, filtered, 
and concentrated in vacuo affording the methyl enol ether which was used in next step without 
further purification. 
      To the solution of methyl enol ether prepared above in acetone (50 mL), PTSA·H2O (260 mg, 
1.37 mmol) was added one portion at 0 ⁰C. The reaction was stirred at room temperature for 30 
minutes and solvent was removed in vacuo. The residue was taken up in water (20 mL) + CH2Cl2  
(20 mL). The organic fraction was separated and the aqueous was extracted with CH2Cl2 (2 x 20 
mL). Combined organic portions were dried on MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by a flash column chromatography (SiO2, eluting with 
EtOAc/hexanes = 1:4) affording aldehyde 42 (1.145 g, 79%, 2 steps) as a colorless oil. [α]D25 
+2.44 (c 1.31, CH3OH). 1H NMR (400 MHz, CDCl3) δ 9.71 (d, J = 52.8, 1H), 9.71 (d, J = 52.8, 
1H), 7.63 (s, 4H), 7.25-7.44 (m, 11H), 5.10 (d, J = 6.2, 2H), 4.22-4.36 (m, 1H), 4.04 (s, 1H), 
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3.69 (s, 2H), 2.78-3.11 (m, 1H), 2.36-2.45 (m, 1H),  1.39-2.27 (m, 6H), 1.03 (s, 9H). 13C NMR 
(75 MHz, CDCl3) δ 200.9, 136.8, 135.8, 133.9, 129.9, 128.7, 128.1, 127.9,  127.2, 67.1, 67.0, 
61.8, 56.4, 55.8, 54.2, 52.9, 50.3, 48.1, 38.4, 36.5, 30.4, 29.7, 28.5, 27.7, 27.1, 19.4. Anal. Calcd 
for C32H39NO4Si: C, 72.55; H, 7.42; N, 2.64. Found: C, 72.55; H, 7.39; N, 2.57. 
 
 
      (2S,5R)-benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2-hydroxyethyl)pyrrolidine-1-
carboxylate (43) Aldehyde 42 (530 mg, 1 mmol)  was dissolved in 15 mL MeOH. At 0 °C, 
NaBH4 (80 mg, 2 mmol) was added by three portions and stirred for 30 minutes. The reaction 
was warmed to room temperature and stirred for 15 minutes. The solvent was removed under 
reduced pressure. The residue was portioned between sat. NaCl (20 mL) and DCM (30 mL). The 
organic fraction was separated and the aqueous was extracted with DCM (30 mL). Combined 
organic portions were dried on anhydrous MgSO4, filtered, and concentrated in vacuo. The 
residue was purified by a flash chromatography. 
 
 
      (2S,5S)-benzyl 2-(2-(tert-butyldiphenylsilyloxy)ethyl)-5-(2-(2,6-
dioxocyclohexyl)ethyl)pyrrolidine-1-carboxylate (44) Aldehyde 43 (462 mg, 0.872 mmol, 1.0 
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equiv) was dissolved in CH2Cl2 (1.75 mL). Diethyl 2,6-dimethyl-1,4-dihydropyridine-3,5-
dicarboxylate (221 mg, 0.872 mmol, 1.0 equiv) and cyclohexane-1,3-dione (98 mg, 0.872 mmol, 
1.0 equiv) were added subsequently. Then L-proline (20 mg, 0.175 mmol, 0.2 equiv) was added 
to the mixture. The stirring was continued for 1 hour. The resulting mixture was directly 
subjected to purify by a flush column chromatography (SiO2, 50:50 hexanes/EtOAc) to afford 
509 mg (93% yield) of 44 as a colorless oil. [α]D25 +42.1 (c 0.4, CH3OH). 1H NMR (400 MHz, 
CDCl3) δ 7.60-7.64 (m, 4H), 7.26-7.45 (m, 11H), 5.15 (d, J = 2.0, 2H), 4.00-4.09 (m, 1H), 3.60-
3.81 (m, 3H), 2.15-2.54 (m, 6H), 1.35-1.97 (m, 11H), 0.98 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 
199.4, 135.7, 133.8, 129.9, 128.7, 128.3, 128.2, 127.9, 114.7, 67.8, 61.7, 58.7, 56.9, 39.2, 37.2, 
37.0, 31.7, 30.0, 29.7, 27.0, 21.1, 19.4, 19.2, 14.4. Anal. Calcd for C38H47NO5Si·H2O: C, 70.88; 
H, 7.67; N, 2.18. Found: C, 70.98; H, 7.46; N, 2.18. 
 
 
      (1S,3aS)-1-(2-(tert-butyldiphenylsilyloxy)ethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-
a]quinolin-6(7H)-one (45) Compound 44 (473 mg, 0.756 mmol, 1.0 equiv) was dissolved in 
methanol (100 mL). 10% Pd/C (245 mg) was added to the solution. The mixture was subjected to 
hydrogenation with hydrogen balloon at room temperature for 24 hours. The resulting mixture 
was filtered through celite 545 (5 g) and rinsed with methanol (2 × 50 mL). All the combined 
filtrates were concentrated under vacuum. The residue was purified by preparative TLC (SiO2, 
95:5 EtOAc/CH3OH) to afford 270 mg (75% yield) of 45 as a yellow oil. [α]D25 +317 (c 0.31, 
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CH3OH). 1H NMR (400 MHz, CDCl3) δ 7.65 (dt, J = 8.0, 1.6, 4H), 7.37-7.47 (m, 6H), 4.03 (t, J 
= 8.6, 1H), 3.58-3.78 (m, 2H), 3.20-3.28 (m, 1H), 2.60-2.75 (m, 2H), 2.26-2.43 (m, 3H), 1.38-
2.20 (m, 10H), 1.13-1.28 (m, 1H), 1.06 (d, J = 7.7, 9H). 13C NMR (75 MHz, CDCl3) δ 193.9, 
158.9, 135.8, 135.7, 133.6, 130.1, 128.0, 107.3, 61.4, 61.0, 59.4, 57.3, 56.4, 55.7, 38.9, 38.5, 36.6, 
36.3, 30.7, 29.8, 29.1, 28.6, 27.8, 27.6, 27.4, 27.1, 22.1, 21.6, 20.3, 19.4. Anal. Calcd for 
C30H39NO2Si·0.5H2O: C, 74.64; H, 8.35; N, 2.90. Found: C, 74.51; H, 8.28; N, 2.95. 
 
 
      (1S,3aS)-1-(2-hydroxyethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-a]quinolin-6(7H)-one 
(9) Silyl ether 45 (174 mg, 0.367 mmol) was dissolved in THF (5 mL). At 0 ⁰C, 
Tetrabutylammoniumfluoride (1.0 M in THF, 0.55 mL) was added dropwise to the solution. The 
reaction was stirred at room temperature for 3 hours and quenched by the addition of satuarted 
Na2CO3 solution (0.5 mL). The reaction mixture was partitioned in EtOAc (20 mL) + brine (20 
mL). The organic fraction was separated and the aqueous was extracted with EtOAc (2 x 20 mL). 
Combined organic fractions were dried on anhydrous MgSO4, filtered, and concentrated in vacuo. 
The residue was purified by preparative TLC (SiO2, eluting with CH3OH/CH2Cl2 = 8:92) 
affording Kishi’s Intermediate 9 (75 mg, 87% yield) as a white solid, mp 178-180 °C 
(recrystallization from EtOAc/cyclohexane, 1:1) {lit.10: mp 176-179 °C }. [α]D25 +798 (c 0.29, 
EtOH) {lit.10: [α]D25 +538 (c 1.40, EtOH)}. 1H NMR (400 MHz, CDCl3) δ 4.03 (t, J = 8.0, 1H), 
3.61-3.78 (m, 2H), 3.23-3.31 (m, 1H), 2.61- 2.68 (m, 2H), 2.40-2.48 (m, 1H), 2.32 (t, J = 6.5, 
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2H), 1.49-2.20 (m, 11H), 1.18-1.29 (m, 1H).  13C NMR (75 MHz, CDCl3) δ 193.7, 158.9, 107.1, 
60.0, 59.3, 55.6, 38.5, 36.3, 29.6, 29.0, 28.4, 27.3, 21.9, 21.4.  
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APPENDIX 
 
 
Crystal Structure of 
(1S,3aS)-1-(2-hydroxyethyl)-1,2,3,3a,4,5,8,9-octahydropyrrolo[1,2-a]quinolin-6(7H)-one (6)- 
Kishi’s intermediate 
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Table 1.  Crystal data and structure refinement for Kishi’s intermediate (6) 
 
Empirical formula  C14H21NO2 
Formula weight  235.32 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group  P2(1)2(1)2(1) 
Unit cell dimensions a = 8.83600(10) Å aα= 90o. 
 b = 10.49690(10) Å bβ= 90o. 
 c = 13.3180(2) Å gγ= 90o. 
Volume 1235.25(3) Å3 
Z 4 
Density (calculated) 1.265 Mg/m3 
Absorption coefficient 0.084 mm-1 
F(000) 512 
Crystal size 0.80 x 0.40 x 0.20 mm3 
Theta range for data collection 2.47 to 32.49o. 
Index ranges -13<=h<=13, -15<=k<=15, -20<=l<=20 
Reflections collected 52997 
Independent reflections 4454 [R(int) = 0.0208] 
Completeness to theta = 32.49o 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9834 and 0.9360 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4454 / 0 / 238 
Goodness-of-fit on F2 1.080 
Final R indices [I>2sigma(I)] R1 = 0.0285, wR2 = 0.0805 
R indices (all data) R1 = 0.0291, wR2 = 0.0814 
Absolute structure parameter -0.4(6) 
Largest diff. peak and hole 0.371 and -0.182 e. Å-3 
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Table 2. Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 103) 
for Kishi’s intermediate (6). U(eq) is defined as one third of the trace of the orthogonalized Uij 
tensor. 
 
______________________________________________________________________ 
 x y z U(eq) 
______________________________________________________________________ 
N(1) 4153(1) 1342(1) 10115(1) 17(1) 
C(2) 3935(1) 2114(1) 9329(1) 15(1) 
C(3) 4005(1) 1532(1) 8296(1) 18(1) 
C(4) 3347(1) 2399(1) 7496(1) 22(1) 
C(5) 3991(1) 3732(1) 7589(1) 23(1) 
C(6) 3814(1) 4264(1) 8634(1) 19(1) 
O(7) 3770(1) 5442(1) 8756(1) 30(1) 
C(8) 3741(1) 3415(1) 9468(1) 17(1) 
C(9) 3499(1) 3977(1) 10499(1) 21(1) 
C(10) 3235(1) 2945(1) 11285(1) 23(1) 
C(11) 4368(1) 1876(1) 11127(1) 20(1) 
C(12) 4237(1) 717(1) 11810(1) 28(1) 
C(13) 4756(1) -383(1) 11141(1) 25(1) 
C(14) 4075(1) -59(1) 10114(1) 18(1) 
C(15) 2438(1) -520(1) 10005(1) 20(1) 
C(16) 2333(1) -1923(1) 9743(1) 25(1) 
O(17) 2895(1) -2090(1) 8753(1) 30(1) 
______________________________________________________________________ 
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Table 3. Bond lengths [Å] and angles [o] for Kishi’s intermediate (6). 
_____________________________________________________  
N(1)-C(2)  1.3386(8) 
N(1)-C(11)  1.4716(8) 
N(1)-C(14)  1.4719(8) 
C(2)-C(8)  1.3881(8) 
C(2)-C(3)  1.5069(8) 
C(3)-C(4)  1.5174(10) 
C(4)-C(5)  1.5161(11) 
C(5)-C(6)  1.5079(10) 
C(6)-O(7)  1.2480(8) 
C(6)-C(8)  1.4257(9) 
C(8)-C(9)  1.5093(9) 
C(9)-C(10)  1.5238(11) 
C(10)-C(11)  1.5185(10) 
C(11)-C(12)  1.5236(11) 
C(12)-C(13)  1.5287(12) 
C(13)-C(14)  1.5328(10) 
C(14)-C(15)  1.5323(9) 
C(15)-C(16)  1.5154(10) 
C(16)-O(17)  1.4202(10) 
 
C(2)-N(1)-C(11)        120.27(5) 
C(2)-N(1)-C(14) 126.66(6) 
C(11)-N(1)-C(14) 112.84(5) 
N(1)-C(2)-C(8) 120.59(6) 
N(1)-C(2)-C(3) 117.54(5) 
C(8)-C(2)-C(3) 121.75(5) 
C(2)-C(3)-C(4) 112.46(5) 
C(5)-C(4)-C(3) 110.61(6) 
C(6)-C(5)-C(4) 112.26(6) 
O(7)-C(6)-C(8) 121.18(7) 
O(7)-C(6)-C(5) 119.32(7) 
C(8)-C(6)-C(5) 119.48(6) 
C(2)-C(8)-C(6) 120.35(6) 
C(2)-C(8)-C(9) 121.56(6) 
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Table 3 (Continued). Bond lengths [Å] and angles [o] for Kishi’s intermediate (6). 
 
C(6)-C(8)-C(9) 118.06(6) 
C(8)-C(9)-C(10) 111.63(6) 
C(11)-C(10)-C(9) 109.21(6) 
N(1)-C(11)-C(10) 108.87(6) 
N(1)-C(11)-C(12) 103.45(6) 
C(10)-C(11)-C(12) 117.22(6) 
C(11)-C(12)-C(13) 103.40(6) 
C(12)-C(13)-C(14) 103.61(6) 
N(1)-C(14)-C(15) 111.12(5) 
N(1)-C(14)-C(13) 101.62(6) 
C(15)-C(14)-C(13) 112.63(6) 
C(16)-C(15)-C(14) 112.74(6) 
O(17)-C(16)-C(15) 108.17(6) 
_____________________________________________________________  
Symmetry transformations used to generate equivalent atoms:  
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